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Differences by Sex in Tobacco 
Use and Awareness of Tobacco 
Marketing — Bangladesh, 
Thailand, and Uruguay, 2009
The majority of the world’s 1.3 billion tobacco users are men, 
but female use is increasing (1,2). To examine differences in 
tobacco use and awareness of tobacco marketing by sex, CDC 
and health officials in Bangladesh, Thailand, and Uruguay 
(among the first countries to report results) analyzed 2009 data 
from a newly instituted survey, the Global Adult Tobacco Survey 
(GATS). This report summarizes the results of that analysis, 
which indicated wide variation among the three countries in 
tobacco use, product types used, and marketing awareness 
among males and females. In Bangladesh and Thailand, use of 
smoked tobacco products was far greater among males (44.7% 
and 45.6%, respectively) than females (1.5% and 3.1%, respec-
tively). In Uruguay, the difference was smaller (30.7% versus 
19.8%). Use of smokeless tobacco products in Bangladesh was 
approximately the same among males (26.4%) and females 
(27.9%), but females were significantly more likely to use 
smokeless tobacco in Thailand (6.3% versus 1.3%), and use in 
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World No Tobacco Day — 
May 31, 2010
Tobacco use is the leading cause of preventable death 
worldwide and is estimated to kill 5 million persons 
each year. According to the World Health Organization 
(WHO), if current trends continue, by 2030 tobacco 
use could cause 8 million deaths annually (1).
WHO created World No Tobacco Day in 1987 to 
draw global attention to tobacco use and the prevent-
able death and disease it causes. The theme for this 
year’s World No Tobacco Day, which will be held on 
May 31, is “gender and tobacco, with an emphasis on 
marketing to women.”
Although women account for only about 20% of 
the world’s 1 billion smokers, female smoking rates are 
on the rise (2), and tobacco advertising increasingly 
targets girls and women (3). World No Tobacco Day 
this year emphasizes the importance of controlling 
tobacco use among women and understanding the 
differences between males and females in tobacco use, 
awareness of tobacco advertising and marketing, and 
the health effects of tobacco use. Additional informa-
tion regarding World No Tobacco Day is available on 
the Internet (2).
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Uruguay by either sex was nearly nonexistent. Males 
in Bangladesh were twice as likely as females to notice 
cigarette advertising (68.0% versus 29.3%), but the 
difference between males and females was smaller in 
Thailand (17.4% versus 14.5%) and Uruguay (49.0% 
versus 40.0%). In all three countries, awareness of 
tobacco marketing was more prevalent among females 
aged 15–24 years than older women. Comprehensive 
bans on advertising, sponsorship, and promotion of 
tobacco products, recommended by the World Health 
Organization (WHO) (1), can reduce per capita 
cigarette consumption if enforced (3).
GATS* is a new nationally representative house-
hold survey of persons aged ≥15 years, initially 
conducted during 2008–2009 in 14 countries: 
Bangladesh, Brazil, China, Egypt, India, Mexico, 
Philippines, Poland, Russian Federation, Thailand, 
Turkey, Ukraine, Uruguay and Vietnam. Bangladesh, 
Thailand, and Uruguay were among the first coun-
tries to report results. The GATS core questionnaire 
includes detailed questions regarding the demographic 
characteristics of respondents, their tobacco use, and 
a wide range of tobacco-related topics (e.g., cessation, 
secondhand smoke, economics, media, and knowl-
edge, attitudes, and perceptions). In each country, 
a multistage cluster sample design is used, with the 
number of households selected proportionate to 
population size. Households are chosen randomly 
within a primary sampling unit or secondary sampling 
unit, and one respondent is selected at random from 
each selected household to participate in the survey. 
Interviewers administer the survey in the country’s 
local language, using handheld electronic data col-
lection devices. Interviews are conducted privately 
and same-sex interviewers are used in countries where 
culturally appropriate (e.g., Bangladesh). Response 
rates and number of participants for the three coun-
tries in 2009 were as follows: Bangladesh, 93.6% and 
9,629; Thailand, 94.2% and 20,566; and Uruguay, 
95.6% and 5,581.
To examine differences in tobacco use by sex, esti-
mates of current tobacco use† in the three countries 
were analyzed for both smoked tobacco products§ and 
† Percentage of respondents who reported currently smoking tobacco 
or using smokeless tobacco on a “daily” or “less than daily” basis.
§ In Bangladesh, these included manufactured cigarettes, bidis, and other 
smoked products such as cigars, pipes, and water pipes. In Thailand and 
Uruguay, they included manufactured and hand-rolled cigarettes.
* Additional information available at http://www.cdc.gov/tobacco/
global/gats.
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smokeless tobacco products.¶ To examine differences 
in tobacco marketing awareness by sex, “yes” responses 
were analyzed to questions regarding whether partici-
pants had noticed advertising, promotion, or sponsor-
ship of cigarettes in the preceding 30 days. Estimates 
were reported for noticing any cigarette marketing, 
noticing marketing in stores where cigarettes are 
sold, and noticing marketing other than in stores 
where cigarettes are sold.** In Bangladesh, similar 
questions regarding bidi†† and smokeless tobacco 
marketing were included in the survey. All estimates 
were weighted to reflect the noninstitutionalized 
population aged ≥15 years in each country, account-
ing for clustered sampling in the variance estimation. 
Statistical significance of differences in values was 
determined using a chi-square test, with significance 
determined at p<0.05.
In all three countries, current tobacco use was 
higher among males than females, but use of tobacco 
varied substantially by sex. In Bangladesh, overall 
smoking prevalence among females (1.5%) was far 
lower than males (44.7%) (Table 1). However, the 
prevalence of smokeless tobacco use among females 
(27.9%) and males (26.4%) was approximately the 
same. In Thailand, smoking prevalence was much 
lower among females, compared with males (3.1% 
versus 45.6%), but smokeless tobacco use was higher 
among females than males (6.3% versus 1.3%, respec-
tively). In Uruguay, 19.8% of females were current 
smokers, compared with 30.7% of males, but only 
one of the 5,581 participants reported using smoke-
less tobacco.
Regardless of age group or region type (urban or 
rural), males were more likely to smoke than females 
in all three countries. Among both males and females, 
 ¶ In Bangladesh, these included betel quid with tobacco, sada pata, 
gul, khoinee zarda, and pan masala. In Thailand, they include betel 
quid with tobacco. In Uruguay, they included any smokeless or 
chew tobacco product; however, only one respondent in Uruguay 
indicated smokeless tobacco use.
 ** Noticing any cigarette marketing included noticing advertisements 
or signs promoting cigarettes, cigarette company sponsorship 
of sporting events, or cigarette promotions in the preceding 30 
days. Noticing cigarette marketing in stores where cigarettes 
are sold included noticing cigarettes at sale prices, free gifts, or 
discount offers on other products while buying cigarettes, or 
any advertisements or signs promoting cigarettes in stores where 
cigarettes are sold in the preceding 30 days. Noticing cigarette 
marketing in places other than in stores where cigarettes are sold 
included noticing any advertisements or signs promoting cigarettes, 
cigarette company sponsorship of sporting events, or cigarette 
promotions in the preceding 30 days other than in stores where 
cigarettes are sold.
 †† Hand-rolled cigarettes made of tobacco flakes wrapped in a 
temburini or tendu leaf and tied with a string.
TABLE 1.  Current tobacco use among persons aged ≥15 years, by sex and selected characteristics — Global Adult Tobacco Survey, Bangladesh, 




















 % (95% CI*)  % (95% CI)  % (95% CI)  % (95% CI)  % (95% CI)  % (95% CI)
Overall  58.0 (55.9–60.1)  28.7 (26.7–30.8)†  46.4 (44.6–48.2)  9.1 (8.2–10.2)†  30.7 (28.2–33.4)  19.8 (18.1–21.6)†
Smoked tobacco products§  44.7 (42.5–47.0)  1.5 (1.1–2.1)†  45.6 (43.8–47.4)  3.1 (2.7–3.6)†  30.7 (28.2–33.4)  19.8 (18.1–21.6)†
 Age group (yrs)
  15–24  24.0 (20.4–28.0)  0.4 (0.1–1.0)†  37.4 (32.5–42.6)  1.4 (0.9–2.3)†  28.9 (23.4–35.0)  20.2 (15.6–25.8)†
  25–44  53.1 (50.1–56.1)  1.1 (0.6–2.0)†  51.4 (49.1–53.7)  2.3 (1.8–3.0)†  35.0 (30.7–39.5)  26.0 (22.7–29.5)†
  45–64  57.9 (53.6–62.2)  2.6 (1.7–4.0)†  45.2 (42.9–47.6)  4.4 (3.5–5.5)†  34.9 (30.4–39.7)  22.8 (19.1–27.1)†
  ≥65  39.1 (32.7–45.9)  6.6 (3.5–12.2)†  37.7 (34.2–41.4)  5.6 (4.2–7.4)†  13.2 (9.8–17.5)  5.2 (3.8–7.1)†
 Region type
  Urban  42.1 (39.5–44.7)  0.8 (0.5–1.2)†  41.9 (40.1–43.7)  3.3 (2.8–3.8)†  30.9 (28.1–33.8)  20.0 (18.2–21.9)†
  Rural  45.6 (42.8–48.5)  1.8 (1.2–2.6)†  47.1 (44.7–49.6)  3.0 (2.4–3.8)†  28.9 (25.0–33.1)  16.7 (12.7–21.7)†
Smokeless tobacco products¶  26.4 (24.2–28.6)  27.9 (25.9–30.0)  1.3 (1.1–1.7)  6.3 (5.5,7.2)†  0.0 (0.0–0.1) —**
 Age group (yrs)
  15–24  9.3 (6.6–12.9)  4.0 (2.9–5.6)†  0.1 (0.0–0.5) — — —
  25–44  27.0 (24.3–29.9)  26.6 (23.9–29.5)  0.5 (0.3–1.0)  0.7 (0.4–1.1) — —
  45–64  40.4 (36.0–44.9)  56.2 (52.1–60.3)†  1.6 (1.1–2.2)  8.5 (7.0–10.3)†  0.0 (0.0–0.3) —
  ≥65  49.3 (42.8–55.8)  64.1 (56.3–71.2)†  7.5 (5.6–9.9)  32.9 (28.9–37.1)† — —
 Region type
  Urban  21.6 (19.0–24.4)  23.4 (20.6–26.4)  0.8 (0.6–1.1)  2.2 (1.7–2.8)† — —
  Rural  28.1 (25.3–31.0)  29.6 (27.1–32.1)  1.5 (1.2–2.0)  8.3 (7.1–9.6)†  0.1 (0.0–0.9) —
 * Confidence interval.
 † Significant difference between females and males (p<0.05, chi-square test).
 § In Bangladesh, these include manufactured cigarettes, bidis, and other smoked products such as cigars, pipes, and water pipes. In Thailand and Uruguay, they include manufactured and 
hand-rolled cigarettes.
 ¶ In Bangladesh, these include betel quid with tobacco, sada pata, gul, khoinee zarda, and pan masala. In Thailand, they include betel quid with tobacco. In Uruguay, they include any 
smokeless or chew tobacco product; however, only one respondent in Uruguay indicated smokeless tobacco use.
 ** No respondent in category reported use.
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smoking prevalence varied by age group but did 
not vary greatly by region type. In Bangladesh and 
Thailand, smokeless tobacco use among both males 
and females increased with age group, and smokeless 
tobacco use was higher in rural than urban areas. 
In each of these countries, the greatest prevalence 
of smokeless tobacco use was among women aged 
≥65 years: 64.1% in Bangladesh and 32.9% in 
Thailand.
The percentage of females who noticed any ciga-
rette advertising, sponsorship, or promotion in the 
preceding 30 days was 29.3% in Bangladesh, 14.5% 
in Thailand, and 40.0% in Uruguay (Table 2). Among 
males, the prevalence was 68.0% in Bangladesh, 
17.4% in Thailand, and 49.0% in Uruguay. Among 
females, awareness of cigarette marketing in stores 
where cigarettes are sold was 22.0% in Bangladesh, 
7.6% in Thailand, and 24.0% in Uruguay. In Thailand 
and Uruguay, little or no difference in awareness of in-
store cigarette marketing was observed between males 
and females; however, in Bangladesh, the prevalence 
among males (54.8%) was more than double the 
prevalence among females. Similar patterns by sex 
were observed for awareness of cigarette marketing 
other than in stores where cigarettes are sold. The 
percentage of females who noticed tobacco advertis-
ing, sponsorship, or promotion other than in stores 
where cigarettes are sold was 16.5% in Bangladesh, 
8.3% in Thailand, and 31.6% in Uruguay.
In all three countries, awareness of cigarette adver-
tising was greater among females aged 15–24 years 
than women aged ≥25 years. Similar age differences 
were observed among males in all three countries. In 
Bangladesh, awareness of bidi (80.1%) and smokeless 
tobacco (69.9%) marketing was widespread among 
females and did not vary by age. In Thailand, for both 
males and females, those who lived in urban areas were 
more likely to report exposure to cigarette marketing 
than those in rural areas. This relationship also was 
observed among males in Uruguay. In contrast, aware-
ness of both bidi and smokeless tobacco marketing in 
Bangladesh was more common among males in rural 
areas than in urban areas (Table 2).
Reported by
S Choudhury, PhD, National Heart Foundation Hospital & 
Research Institute, Dhaka, Bangladesh. M Kengganpanich, 
PhD, Thailand Mahidol Univ; S Benjakul, PhD, Thailand 
Ministry of Public Health. A Lorenzo, MD, W Abascal, MD, 
National Tobacco Control Program, Uruguay Ministry of 
Health. BJ Apelberg, PhD, Johns Hopkins Bloomberg School 
of Public Health. SA Mirza, L Zhao, J Hsia, KM Palipudi, 
L Andes, J Morton, S Asma. Global Tobacco Control Br, Office 
on Smoking and Health, National Center for Chronic Disease 
Prevention and Health Promotion, CDC.
Editorial Note
This report is the first to compare results among 
countries that participated in GATS. The findings 
demonstrate the wide variation in prevalence of 
tobacco use and types of tobacco used by males and 
females in Bangladesh, Thailand, and Uruguay and 
also the widespread exposure to tobacco marketing 
in these three countries, particularly among persons 
aged 15–24 years. Although tobacco use surveys have 
been conducted previously in all three countries, the 
results from GATS are the first that allow comparison 
among countries using the same core questionnaire 
and survey method.
One finding from these surveys is the lower 
prevalence of current smoking among females in 
Bangladesh and Thailand compared with males, 
but the higher prevalence of smokeless tobacco use 
among females. This reflects the traditional social 
acceptance of smokeless tobacco use among females 
in Southeast Asian countries (4), where older women 
are more likely to be users. In contrast, in Uruguay, 
smokeless tobacco use by either sex is virtually non-
existent. Tobacco use in individual countries reflects 
a complex interaction of personal, familial, cultural, 
and social factors, including exposure to tobacco 
industry marketing (5). For example, in the United 
States, girls and young women have been shown to 
be particularly susceptible to beliefs about self-image 
What is already known on this topic?
Before the advent of the Global Adult Tobacco Survey 
(GATS), comparative data on tobacco prevalence and 
awareness of tobacco marketing among countries 
were not available.
What is added by this report?
GATS results for three of the first countries to have 
data available, Bangladesh, Thailand, and Uruguay, 
indicate wide variation in tobacco use, products used, 
and awareness of tobacco product marketing among 
males and females.
What are the implications for public health practice?
Implementation of the World Health Organization’s 
MPOWER strategy can effectively reduce tobacco use 
and its associated illness and deaths.
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and weight control, and might be influenced more 
by female friends and role models who smoke or use 
tobacco (5).
GATS survey results like these can be used to 
better understand comparative patterns of tobacco 
use among countries, which, in turn, can be used to 
create more effective control programs and monitor 
the impact of these programs. GATS was created to 
enable systematic monitoring of tobacco use by per-
sons aged ≥15 years and key tobacco-control indica-
tors in low- and middle-income countries. Over time, 
GATS will provide detailed information on a range 
of tobacco-control topics, including cessation, sec-
ondhand smoke, economics, media, and knowledge, 
attitudes, and perceptions.
The theme of WHO’s World No Tobacco Day 
2010 (May 31) is “gender and tobacco with an 
emphasis on marketing to women.” Tobacco market-
ing is important to the initiation and maintenance of 
tobacco use (6). In all three countries in this report, 
greater awareness of cigarette marketing was found 
among females aged 15–24 years than older women, 
TABLE 2. Awareness of tobacco marketing in the past 30 days among persons aged ≥15 years, by sex, marketing type, and selected characteristics — 




















 % (95% CI*)  % (95% CI)  % (95% CI*)  % (95% CI*)  % (95% CI*)  % (95% CI*)
Noticed any cigarette advertising, 
sponsorship, or promotion†
 68.0 (64.9–71.0)  29.3 (26.1–32.6)§  17.4 (15.8–19.0)  14.5 (13.0–16.0)§  49.0 (46.0–52.0)  40.0 (37.2–42.8)§
 Age group (yrs)
  15–24  73.1 (68.0–77.7)¶  37.9 (33.5–42.5)¶  25.1 (21.1–29.6)¶  28.1 (23.7–32.8)¶  60.1 (53.4–66.5)¶  62.5 (55.4–69.0)¶
  ≥25  65.9 (62.6–69.0)  25.6 (22.4–29.1)  15.3 (13.9–16.8)  11.2 (10.1–12.5)  45.8 (42.9–48.9)  34.9 (32.2–37.7)
 Region type
  Urban  67.6 (63.3–71.7)  28.6 (23.3–34.6)  22.0 (20.3–23.8)**  17.4 (15.9–19.1)**  49.8 (46.6–53.0)**  40.2 (37.3–43.3)
  Rural  68.1 (64.1–71.8)  29.5 (25.7–33.6)  15.3 (13.3–17.6)  13.1 (11.1–15.3)  40.7 (35.9–45.6)  35.6 (31.2–40.4)
In stores where cigarettes are sold††  54.8 (51.7–57.9)  22.0 (19.1–25.3)§  8.3 (7.1–9.6)  7.6 (6.5–8.9)  29.9 (27.1–32.8)  24.0 (21.6–26.5)§
 Age group (yrs)
  15–24  58.9 (53.7–64.0)¶  28.2 (24.2–34.5)¶  12.1 (9.3–15.7)¶  15.2 (11.7–19.6)¶  40.1 (34.5–45.9)¶  41.8 (35.2–48.6)¶
  ≥25  53.1 (49.8–56.3)  19.4 (16.4–22.8)  7.3 (6.2–8.4)  5.8 (4.9–6.8)  27.0 (24.0–30.1)  20.0 (17.8–22.4)
 Region type
  Urban  52.5 (48.1–56.9)  19.5 (15.2–24.6)  10.1 (8.9–11.5)**  8.9 (7.6–10.3)  30.6 (27.6–33.7)**  24.5 (22.0–27.2)**
  Rural  55.6 (51.7–59.5)  22.9 (19.3–27.0)  7.5 (6.0–9.3)  7.0 (5.6–8.8)  22.3 (18.8–26.3)  16.2 (12.7–20.4)
Other than in stores where cigarettes 
are sold§§
 47.7 (44.4–51.0)  16.5 (14.2–19.1)§  11.1 (9.9–12.3)  8.3 (7.3–9.5)§  39.6 (36.6–42.6)  31.6 (29.0–34.4)§
 Age group (yrs)
  15–24  53.9 (48.4–59.4)¶  22.2 (18.7–26.1)¶  16.6 (13.3–20.5)¶  16.5 (13.2–20.4)¶  47.1 (40.3–54.1)¶  50.3 (43.4–57.1)¶
  ≥25  45.1 (41.9–48.4)  14.1 (11.9–16.6)  9.6 (8.5–10.7)  6.4 (5.6–7.3)  37.4 (34.3–40.5)  27.5 (25.0–30.1)
 Region type
  Urban  50.5 (46.6–54.4)  17.6 (13.6–22.5)  14.7 (13.3–16.1)**  10.5 (9.4–11.7)**  40.1 (36.8–43.4)**  31.8 (29.0–34.7)
  Rural  46.7 (42.5–50.9)  16.1 (13.4–19.3)  9.5 (7.9–11.3)  7.3 (5.9–9.0)  34.2 (29.9–38.7)  29.7 (25.5–34.2)
Noticed any bidi advertising, 
sponsorship, or promotion
 85.9 (81.8–89.2)  80.1 (73.7–85.4) NA¶¶ NA NA NA
 Age group (yrs)
  15–24  88.5 (82.8–92.5)  83.0 (77.3–88.8) NA NA NA NA
  ≥25  84.8 (80.4–88.3)  78.2 (70.4–84.3) NA NA NA NA
 Region type
  Urban  76.1 (69.9–81.3)**  74.2 (63.7–82.5) NA NA NA NA
  Rural  89.2 (83.8–92.9)  81.9 (73.7–88.0) NA NA NA NA
Noticed any smokeless tobacco advertising, 
sponsorship, or promotion
 70.8 (64.1–76.7)  69.9 (61.4–77.2) NA NA NA NA
 Age group (yrs)
  15–24  74.1 (64.1–82.0)  69.3 (60.3–77.0) NA NA NA NA
  ≥25  69.4 (62.4–75.7)  70.2 (60.6–78.3) NA NA NA NA
 Region type
  Urban  57.6 (49.3–65.5)**  67.0 (54.5–77.5) NA NA NA NA
  Rural  76.0 (66.9–83.2)  71.0 (60.0–80.0) NA NA NA NA
 * Confidence interval.
 † Includes any advertisements or signs promoting cigarettes, cigarette company sponsorship of sporting events, or cigarette promotions.
 § Significant difference between females and males (p<0.05, chi-square test).
 ¶ Significant difference between younger and older age group (p<0.05, chi-square test).
 ** Significant difference between urban and rural region type (p<0.05, chi-square test).
 †† Includes cigarettes at sale prices, free gifts, or discount offers on other products while buying cigarettes, or any advertisements or signs promoting cigarettes in stores where cigarettes are sold. 
 §§ Includes any advertisements or signs promoting cigarettes, cigarette company sponsorship of sporting events, or cigarette promotions other than in stores where cigarettes are sold.
 ¶¶ Data not available.
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suggesting that tobacco companies might be target-
ing this age group. Historically, the tobacco industry 
has taken advantage of increasingly liberalized social 
attitudes toward women and increased economic 
empowerment of women to aggressively market and 
sell its products (7). In the absence of effective tobacco 
control policies, this pattern might repeat itself in low- 
and middle-income countries, resulting in a rise in 
tobacco use and tobacco-related disease and death.
Globally, each year, the tobacco industry spends 
tens of billions of dollars on direct and indirect adver-
tising of tobacco products (8). Comprehensive bans 
on tobacco advertising, sponsorship, and promotion 
have been shown to reduce per capita cigarette con-
sumption (3) if adequately enforced. Enforcement 
of bans on tobacco advertising, sponsorship, and 
promotion, is a component of WHO’s MPOWER 
strategy (1). According to WHO, only 26 countries 
have implemented comprehensive bans on direct 
and indirect tobacco advertising, and many do not 
have high levels of compliance (8). Bangladesh and 
Uruguay have a ban on all national television, radio, 
and print media, and on some, but not all, other forms 
of direct and/or indirect advertising of tobacco prod-
ucts. In these countries, enforcement is rated as high, 
but not complete (8). Thailand has a ban on all direct 
and indirect advertising, with the level of enforcement 
rated somewhat lower.§§ The results presented in this 
report indicate that the lowest prevalence of aware-
ness of cigarette marketing, among both males and 
females, was found in Thailand, where prohibition of 
the display of cigarettes packets or logos of tobacco 
brands at the points of sale was enforced beginning 
in 2005.
The findings in this report are subject to at least 
two limitations. First, the prevalence results are based 
on self-reports. In certain settings, social norms (i.e., 
unacceptability of women smoking) might result in 
underreporting. However, this tendency might have 
been mitigated by using same-sex interviewers and 
conducting interviews in private settings. Second, 
regarding the findings on awareness of tobacco 
marketing, slight variations in the number and type of 
specific response categories used in each country might 
limit comparability. For example, Thailand added a 
category of “pubs/bars” as a site for tobacco marketing 
to the core GATS questionnaire and removed “public 
walls.” Uruguay added the category “e-mail” to promo-
tions, and Thailand added a category for the “Internet.” 
Aside from these differences, the response categories 
were similar among the three countries.
Continued monitoring will be needed to deter-
mine trends in tobacco use and awareness of tobacco 
marketing and the differences between males and 
females. Repeated GATS surveys in participating 
countries will allow the countries to compare results to 
other countries, track key tobacco control indicators, 
and monitor progress toward tobacco-control goals.
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question about current treatment for an emotional 
problem, and two attitudinal questions.
The Kessler 6-scale asks respondents how often 
in the past 30 days they felt six symptoms of mental 
illness (i.e., feeling nervous, depressed, hopeless, rest-
less, like a failure, like everything was an effort). Each 
item is scored on a 5-point scale indicating frequency, 
ranging from 0 (none of the time) to 4 (all of the 
time), and summed (score range: 0–24). Respondents 
scoring 13 or more on this scale were classified as hav-
ing serious psychological distress (5). Frequent mental 
distress was measured with the question, “For how 
many days in the past 30 days was your mental health 
(due to stress, depression, or problems with emotions) 
not good?” Respondents reporting 14 or more poor 
mental health days were identified as having frequent 
mental distress. To determine current treatment for an 
emotional problem, survey participants were asked, 
“Are you now taking medicine or receiving treatment 
from a doctor or other health professional for any type 
of mental health condition or emotional problem?”
Attitudes were assessed by asking respondents to 
indicate their level of agreement with two statements. 
The first statement assessed attitude on the effective-
ness of treatment: “Treatment can help people with 
mental illness lead normal lives.” The second state-
ment assessed the respondent’s perception of others’ 
attitudes toward persons with mental illness: “People 
are generally caring and sympathetic to people with 
mental illness.”† Before inclusion in BRFSS, cogni-
tive testing in a sample of the general population 
confirmed that adults understood these questions as 
intended. For example, respondents suggested that 
“normal lives” meant “being able to do everyday 
things, like going to the grocery store, paying bills, 
things that you have to do to live.” The question about 
attitudes toward treatment also demonstrated accept-
able construct validity with expectations regarding 
mental illness recovery.
Data were weighted to estimate population 
parameters. CDC used statistical software to calculate 
unadjusted and adjusted proportions (adjusted for sex, 
Negative attitudes about mental illness often 
underlie stigma, which can cause affected persons to 
deny symptoms; delay treatment; be excluded from 
employment, housing, or relationships; and interfere 
with recovery (1). Understanding attitudes toward 
mental illness at the state level could help target initia-
tives to reduce stigma, but state-level data are scant. 
To study such attitudes, CDC analyzed data from the 
District of Columbia (DC), Puerto Rico, and the 35 
states participating in the 2007 Behavioral Risk Factor 
Surveillance System (BRFSS) (the most recent data 
available), which included two questions on attitudes 
toward mental illness. Most adults (88.6%) agreed 
with a statement that treatment can help persons with 
mental illness lead normal lives, but fewer (57.3%) 
agreed with a statement that people are generally car-
ing and sympathetic to persons with mental illness. 
Responses to these questions differed by age, sex, race/
ethnicity, and education level. Although most adults 
with mental health symptoms (77.6%) agreed that 
treatment can help persons with mental illness lead 
normal lives, fewer persons with symptoms (24.6%) 
believed that people are caring and sympathetic to 
persons with mental illness. This report provides the 
first state-specific estimates of these attitudes and 
provides a baseline for monitoring trends. Initiatives 
that can educate the public about how to support 
persons with mental illness and local programs and 
media support to decrease negative stereotypes of 
mental illness can reduce barriers for those seeking or 
receiving treatment for mental illness (2,3).
To measure attitudes about mental illness through 
BRFSS and other surveys, the Substance Abuse and 
Mental Health Services Administration (SAMHSA) 
and CDC collaborated in 2005 to develop brief 
questions suitable for surveillance (4). BRFSS is an 
ongoing, state-based, random-digit–dialed telephone 
survey of the noninstitutionalized civilian population 
aged ≥18 years.* With SAMHSA and CDC support, 
35 states, DC, and Puerto Rico questioned survey 
respondents to the 2007 BRFSS about mental illness. 
Questions included the Kessler-6 scale of serious psy-
chological distress (5), frequent mental distress, one 
Attitudes Toward Mental Illness — 35 States, District of Columbia, 
and Puerto Rico, 2007
* Additional information available at http://www.cdc.gov/brfss.
† These questions were modified from the 2002 National Scottish Survey 
of Public Attitudes to Mental Health, Well Being and Mental Health 
Problems, included in more recent versions of the survey available at 
http://www.scotland.gov.uk/publications/2009/09/15120147/10.
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age group, racial/ethnic group, education, and house-
hold income) of agreement by state and by serious 
psychological distress, frequent mental distress, and 
mental health treatment, and to account for the com-
plex BRFSS survey design. After adjustment, CDC 
examined differences in proportions across agreement 
categories for both questions by serious psychological 
distress, frequent mental distress, and mental health 
treatment status. The analyses excluded persons who 
responded “did not know” or “refused” to answer 
the questions.§ The sample size included 202,065 
adults. Among the 35 states, DC, and Puerto Rico, 
the median Council of American Survey Research 
Organization (CASRO) response rate was 51% and 
the CASRO cooperation rate was 71.4%.¶
Most adults agreed, either strongly (62.8%) or 
slightly (25.8%), that treatment could help persons 
with mental illness lead normal lives, but responses 
varied by states (Table 1). The highest percentages 
of strongly agreeing with this statement were in 
Connecticut, DC, Louisiana, Oregon, Vermont, 
Virginia, and Washington; the lowest was in Puerto 
Rico (Figure). Proportions for neither agree nor 
disagree ranged from 0.6% (Iowa) to 9.2% (Puerto 
Rico). Younger adults, men, persons other than white 
non-Hispanics, and persons at lower education levels 
were less likely to agree strongly with this statement 
(Table 2).
In contrast with the statement about treatment, 
a lower proportion of adults agreed, either strongly 
(22.3%) or slightly (35.0%), with the statement that 
people are caring and sympathetic to persons with 
mental illness (Table 3). The highest percentages 
of strongly agreeing with this statement occurred 
in Hawaii, Louisiana, Mississippi, Oklahoma, 
Nevada, and New Mexico. The lowest was in Puerto 
Rico. Adults aged 25–54 years, women, white non-
Hispanics and black non-Hispanics, and college 
graduates were less likely to agree with this statement 
(Table 2).
Approximately 4.0% of adults were classified with 
serious psychological distress, 10.0% were classified 
with frequent mental distress, and 10.8% reported 
receiving treatment for an emotional problem. 
Although most adults with mental health symptoms 
(77.6%) agreed strongly or slightly that treatment 
can help persons with mental illness lead normal 
lives, about 17.8% disagreed (Table 2). Fewer respon-
dents with mental health symptoms (24.6%) agreed 
strongly or slightly that people are generally caring and 
sympathetic to persons with mental illness than those 
without such distress or treatment (Table 2).
Reported by
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MSW, C Marshall, Center for Mental Health Svcs, Substance 
Abuse and Mental Health Svcs Admin. RG Palpant, MS, 
J Bigham, TH Bornemann, EdD, Carter Center Mental 
Health Program. R Kobau, MPH, MAPP, M Zack, MD, 
G Langmaid, W Thompson, PhD, D Lubar, MSW, Div of 
Adult and Community Health, National Center for Chronic 
Disease Prevention and Health Promotion, CDC.
Editorial Note
This is the first state-specific study of attitudes 
toward mental illness treatment and empathy toward 
persons with mental illness. The study sought to 
assess attitudes related to the course of mental illness 
(i.e., treatment prognosis and possibility of recovery; 
and perception of supportive behaviors) that might 
directly influence seeking treatment or recovery and 
might reflect stigmatizing attitudes amenable to public 
health intervention. In the 37 jurisdictions surveyed, 
most adults believed in the effectiveness of mental 
illness treatment, but fewer agreed that people are 
§ For each question, approximately 2% of respondents answered “did 
not know” and approximately 0.3% of respondents refused to answer 
each question.
¶ The response rate is the percentage of persons who completed 
interviews among all eligible persons, including those who were 
not successfully contacted. The cooperation rate is the percentage of 
persons who completed interviews among all eligible persons who 
were contacted. Rates are available at http://ftp.cdc.gov/pub/data/
brfss/2007summarydataqualityreport.pdf.
What is already known on this subject?
Negative attitudes about mental illness pose barri-
ers for persons needing mental health treatment or 
recovering from mental illness.
What is added by this report?
This report provides the first state-specific estimates 
of attitudes toward persons with mental illness and 
treatment of mental illness. Most adults agreed (89%) 
with the effectiveness of mental illness treatment but 
fewer agreed (57%) that other people are caring and 
sympathetic toward those with mental illness.
What are the implications for public health practice?
Initiatives that can educate the public about how 
to support persons with mental illness and local 
programs and media support to decrease negative 
stereotypes of mental illness can reduce barriers for 
those seeking or receiving treatment for mental illness.
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caring and sympathetic toward persons with mental 
illness. These results have public health implications 
because adverse attitudes about mental illness can 
lead to stigmatization of persons with mental illness. 
In addition, the results have implications for mental 
health treatment because adults who do not believe in 
the effectiveness of mental illness treatment might be 
less likely to seek treatment when needed. Also, per-
sons with mental health symptoms who believe that 
others are not caring and sympathetic toward persons 
with mental illness might be less likely to disclose 
mental health problems to friends, family members, 
colleagues, or other persons who could help.
Some of the adverse attitudes indicated in this 
report might be caused by stigma experienced by 
some respondents (e.g., those with mental health 
problems who received less support at work or at 
home or who experienced exclusion from activities) 
(6). Respondents who perceived adverse attitudes 
about empathy in other persons also might have had 
less contact with persons with mental illness, or also 
might harbor misconceptions about the risks associ-
ated with mental illness symptoms (7).
Although the study did not include all 50 states 
and U.S. territories, state-to-state differences were 
noted, but no clear regional patterns emerged on the 
attitudes studied. Differences might have resulted 
from culture and the social environment (e.g., norms, 
customs, language, lifestyle, and degree of accultura-
tion), differences in how mental health is portrayed 
TABLE 1. Level of agreement* with the statement that treatment can help persons with mental illness lead normal lives,† by state and territory — 













State N %  (95% CI§) %  (95% CI) %  (95% CI) %  (95% CI) % (95% CI)
Alaska 2,365 1.2  (0.7–2.1) 3.7  (2.4–5.5) 1.4  (0.5–3.2) 25.9  (23.0–2 9.1) 63.3  (60.0–66.5)
Arkansas 5,299 1.9 (1.3–2.7) 3.5 (2.8–4.4) 0.7 (0.4–1.0) 23.9 (22.2–25.6) 67.2 (65.4–69.0)
California 5,052 1.8  (1.3–2.5) 4.3  (3.5–5.2) 1.5  (1.1–2.0) 29.6  (27.7–31.5) 61.6  (59.7–63.6)
Colorado 5,423 1.4  (1.0–1.9) 3.8  (3.0–4.8) 0.7  (0.4–1.1) 25.9  (24.3–27.6) 65.3  (63.5–67.0)
Connecticut 6,586 1.1  (0.7–1.6) 2.4  (1.9–3.1) 1.9  (1.4–2.6) 21.6  (20.1–23.1) 71.3  (69.7–72.9)
District of Columbia 3,419 1.5  (1.0–2.1) 2.9  (2.2–3.7) 1.3  (0.7–2.1) 18.3  (16.5–20.2) 74.0  (71.9–76.0)
Georgia 6,838 1.8  (1.3–2.5) 3.8  (3.1–4.6) 3.0  (2.4–3.8) 23.7  (22.1–25.4) 65.3  (63.5–67.1)
Hawaii 6,262 2.4  (1.9–3.0) 4.8  (4.0–5.8) 1.7  (1.3–2.2) 26.9  (25.2–28.6) 59.9  (58.1–61.7)
Illinois 5,030 1.5  (1.0–2.0) 4.0  (3.2–5.0) 0.9  (0.6–1.3) 27.2  (25.4–29.0) 65.0  (63.1–66.9)
Indiana 5,467 1.4  (0.9–2.0) 3.5  (2.8–4.4) 1.3  (0.9–1.7) 26.6  (24.8–28.4) 64.5  (62.6–66.4)
Iowa 4,921 1.3  (0.9–1.9) 3.3  (2.6–4.2) 0.6  (0.3–1.0) 26.0  (24.3–27.8) 66.5  (64.7–68.3)
Kansas 4,081 1.1  (0.7–1.4) 2.6  (1.9–3.3) 2.3  (1.6–2.9) 25.5  (23.8–27.3) 66.2  (64.3–68.1)
Kentucky 6,185 1.7  (1.0–2.8) 1.5  (1.1–2.0) 5.7  (4.7–6.9) 25.2  (23.4–27.0) 62.1  (60.1–64.1)
Louisiana 6,098 2.1  (1.6–2.8) 3.6  (2.8–4.6) 1.9  (1.4–2.6) 16.6  (15.3–18.1) 72.0  (70.3–73.7)
Maine 3,734 1.5  (0.8–2.4) 3.3  (2.5–4.2) 1.0  (0.7–1.6) 23.7  (21.9–25.6) 70.5  (68.5–72.5)
Massachusetts 4,162 2.1  (1.3–3.1) 3.6  (2.7–4.6) 1.8  (1.3–2.5) 23.4  (21.3–25.7) 66.9  (64.5–69.3)
Michigan 4,235 1.6  (1.0–2.6) 3.5  (2.7–4.5) 0.9  (0.5–1.4) 25.2  (23.4–27.1) 65.9  (63.8–67.8)
Minnesota 4,485 —¶ — — — 3.6  (2.9–4.3) 29.2  (27.3–31.2) 67.2  (65.2–69.2)
Mississippi 7,381 2.2  (1.5–3.1) 4.4  (3.6–5.4) 1.3  (1.0–1.7) 21.6  (20.2–23.1) 67.0  (65.3–68.7)
Missouri 4,738 1.5  (1.0–2.1) 3.2  (2.4–4.2) 1.7  (1.1–2.3) 25.1  (23.1–27.3) 68.6  (66.3–70.7)
Montana 5,415 1.6  (1.1–2.3) 3.5  (2.8–4.4) 3.3  (2.6–4.1) 25.9  (24.2–27.6) 62.7  (60.8–64.5)
Nebraska 4,890 1.1  (0.6–1.9) 3.2  (2.3–4.5) 1.7  (1.0–2.8) 24.9  (22.3–27.7) 66.9  (64.0–69.7)
Nevada 3,868 2.0  (1.3–2.8) 3.7  (2.9–4.8) 2.0  (1.3–3.0) 29.2  (26.8–31.7) 60.2  (57.7–62.7)
New Hampshire 5,453 0.9  (0.6–1.3) 3.1  (2.5–3.9) 2.1  (1.6–2.6) 24.3  (22.7–25.9) 67.7  (66.0–69.3)
New Mexico 5,961 1.8  (1.2–2.6) 3.8  (3.1–4.6) 2.4  (1.9–3.0) 24.4  (22.8–26.2) 63.3  (61.5–65.2)
Ohio 5,014 1.2  (0.7–1.7) 3.6  (2.9–4.5) 1.4  (1.0–2.0) 23.0  (21.3–24.7) 68.8  (66.9–70.6)
Oklahoma 6,885 1.2  (0.8–1.6) 3.1  (2.5–3.8) 0.8  (0.5–1.2) 24.1  (22.7–25.6) 66.5  (64.9–68.0)
Oregon 1,898 0.9  (0.4–1.6) 2.2  (1.4–3.5) 1.4  (0.7–2.5) 21.4  (19.0–24.1) 71.7  (68.8–74.4)
Puerto Rico 3,832 1.6  (1.1–2.2) 4.4  (3.6–5.3) 9.2  (8.0–10.6) 56.4  (54.3–58.4) 25.7  (23.9–27.6)
Rhode Island 3,915 1.3  (0.8–2.0) 3.5  (2.7–4.5) 2.9  (2.1–3.8) 28.3  (26.2–30.5) 61.9  (59.7–64.2)
South Carolina 9,889 1.4  (1.1–1.8) 4.4  (3.7–5.1) 1.1  (0.8–1.5) 26.8  (25.4–28.2) 61.6  (60.1–63.1)
Texas 7,386 2.2  (1.8–2.8) 4.9  (4.1–5.8) 4.4  (3.7–5.2) 24.9  (23.2–26.6) 57.9  (56.1–59.7)
Vermont 6,589 1.0  (0.7–1.5) 2.1  (1.6–2.6) 1.4  (1.0–1.9) 22.8  (21.4–24.3) 70.2  (68.6–71.7)
Virginia 5,305 2.1  (1.0–4.2) 2.8  (2.1–3.6) 1.8  (1.3–2.4) 20.8  (19.0–22.7) 70.8  (68.5–72.9)
Washington 13,325 1.5  (1.1–1.9) 3.0  (2.4–3.6) 1.9  (1.5–2.3) 20.8  (19.8–21.9) 70.0  (68.8–71.2)
Wisconsin 4,332 1.5  (1.0–2.1) 4.3  (3.2–5.5) 0.7  (0.4–1.1) 29.8  (27.7–31.9) 61.6  (59.4–63.8)
Wyoming 5,780 0.9  (0.5-1.4) 3.1  (2.4-3.9) 1.5 (1.0-2.0) 26.7 (25.0-28.5) 65.5 (63.7-67.3)
Total 202,065 1.8  (1.6–2.0) 3.9  (3.6–4.1) 2.1  (1.9–2.3) 25.8  (25.3–26.3) 62.8  (62.3–63.4)
* Adjusted for sex, age group, racial/ethnic group, education and household income level. Estimates are weighted; sample size is unweighted. 
† Attitudes were assessed by asking respondents to indicate their level of agreement with the statement, ”Treatment can help people with mental illness lead normal lives.”
§ Confidence intervals. 
¶ Data suppressed because of unstable estimates; before adjustment, about 4% of Minnesota adults disagreed with this statement. 
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FIGURE. Level of agreement* with the statement that people are caring and sympathetic to persons with mental illness,† by state and territory 
— Behavioral Risk Factor Surveillance System, 2007
* Adjusted for sex, age group, racial/ethnic group, education and household income level. Estimates are weighted; sample size is omitted. Neither agree nor disagree 
responses are not shown. 
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TABLE 2.  Level of agreement with statements about mental illness* by demographic characteristics, serious psychological distress, and having 













Statements/Characteristics N %† (95% CI§) % (95% CI) % (95% CI) % (95% CI) % (95% CI)
Treatment can help persons with mental illness lead normal lives
Total† 202,065 1.8 (1.6–2.0) 3.9 (3.6–4.1) 2.1 (1.9–2.3) 25.8 (25.3–26.3) 62.8 (62.3–63.4)
Age group (yrs)            
 18–24 7,286 2.3 (1.7–3.1) 6.8 (5.7–8.0) 2.1 (1.6–2.7) 38.4 (36.2–40.6) 50.5 (48.2–52.7)
 25–34 20,504 1.9 (1.5–2.5) 4.0 (3.5–4.6) 1.9 (1.6–2.3) 31.0 (29.7–32.3) 61.2 (59.8–62.5)
 35–54 72,878 1.4 (1.2–1.7) 2.9 (2.7–3.2) 1.9 (1.6–2.1) 23.9 (23.2–24.6) 69.9 (69.2–70.6)
 ≥55 93,290 1.4 (1.2–1.6) 3.5 (3.2–3.8) 2.5 (2.3–2.7) 23.6 (23.0–24.2) 69.0 (68.4–69.6)
Sex            
Male 72,350 1.9 (1.7–2.2) 4.3 (4.0–4.7) 2.3 (2.1–2.6) 30.7 (29.9–31.5) 60.7 (59.9–61.6)
Female 122,671 1.3 (1.1–1.5) 3.2 (2.9–3.5) 1.9 (1.7–2.1) 23.0 (22.5–23.6) 70.6 (70.0–71.2)
Race/Ethnicity            
White, non-Hispanic 152,980 1.1 (1.0–1.3) 3.0 (2.8–3.3) 1.8 (1.6–2.0) 24.7 (24.2–25.2) 69.4 (68.9–69.9)
Black, non-Hispanic 13,772 2.8 (2.3–3.3) 6.6 (5.6–7.7) 2.4 (1.9–3.0) 26.9 (25.1–28.7) 61.4 (59.6–63.3)
Hispanic 14,689 3.0 (2.4–3.7) 5.1 (4.3–6.0) 3.4 (2.9–4.0) 34.7 (32.9–36.5) 53.8 (52.0–55.7)
Other 12,062 2.1 (1.4–3.0) 4.4 (3.6–5.4) 1.9 (1.4–2.6) 29.9 (27.7–32.2) 61.7 (59.3–64.0)
Educational level            
<High school 18,186 3.4 (2.8–4.1) 5.8 (5.0–6.7) 3.5 (2.9–4.2) 31.9 (30.2–33.7) 55.3 (53.4–57.1)
High school graduate 56,660 1.9 (1.6–2.2) 5.0 (4.5–5.4) 2.4 (2.1–2.7) 30.2 (29.3–31.1) 60.6 (59.7–61.6)
Some college 51,772 1.4 (1.1–1.7) 3.8 (3.4–4.2) 2.0 (1.8–2.3) 27.6 (26.6–28.5) 65.2 (64.2–66.2)
College graduate 68,130 1.0 (0.7–1.3) 2.1 (1.8–2.4) 1.5 (1.3–1.7) 21.7 (21.0–22.4) 73.8 (73.0–74.5)
Mental health symptoms†
Frequent mental distress 20,176 3.1 (2.5–3.6) 5.3 (4.6–5.9) 2.1 (1.7–2.6) 24.8 (23.4–26.1) 61.5 (59.9–63.0)
Serious psychological distress 8,010 5.7 (4.8–6.7) 9.6 (8.3–10.9) 2.3 (1.6–3.1) 24.6 (22.4–26.8) 54.6 (52.0–57.2)
Receiving medicine/treatment from a health 
professional for an emotional problem
26,279 1.8 (1.4–2.1) 3.9 (3.4–4.5) 1.4 (1.2–1.7) 20.3 (19.2–21.4) 70.2 (69.0–71.3)
None of the above 157,176 1.6 (1.4–1.8) 3.8 (3.5–4.1) 2.2 (2.0–2.4) 26.8 (26.3–27.4) 62.4 (61.9–63.0)
All of the above 3,293 6.8 (5.4–8.2) 11.0 (8.8–13.2) 2.3 (1.4–3.2) 25.6 (22.6–28.6) 52.0 (48.5–55.5)
People are generally caring and sympathetic to persons with mental illness
Total† 202,065 10.6 (10.3–10.9) 24.7 (24.3–25.2) 3.2 (3.0–3.4) 35.0 (34.5–35.5) 22.3 (21.9–22.8)
Age group (yrs)
 18–24 7,339 7.7 (6.8–8.8) 23.0 (21.2–24.9) 2.9 (2.3–3.6) 43.5 (41.3–45.7) 22.8 (20.9–24.8)
 25–34 20,579 10.3 (9.6–11.2) 28.3 (27.2–29.5) 3.0 (2.6–3.5) 37.9 (36.6–39.2) 20.4 (19.3–21.7)
 35–54 72,928 12.0 (11.6–12.5) 27.1 (26.5–27.8) 3.3 (3.0–3.6) 37.0 (36.2–37.7) 20.5 (19.9–21.2)
 ≥55 92,814 11.1 (10.7–11.5) 23.5 (22.9–24.0) 3.7 (3.5–4.0) 34.5 (33.9–35.2) 27.2 (26.6–27.8)
Sex
Male 72,578 8.9 (8.4–9.3) 22.9 (22.2–23.6) 3.5 (3.2–3.8) 40.6 (39.8–41.4) 24.1 (23.4–24.9)
Female 122,140 12.9 (12.5–13.3) 28.5 (27.9–29.0) 3.2 (3.0–3.4) 33.9 (33.3–34.5) 21.5 (20.9–22.0)
Race/Ethnicity 
White, non-Hispanic 152,612 11.2 (10.8–11.5) 28.0 (27.5–28.5) 3.2 (3.0–3.4) 38.4 (37.9–38.9) 19.3 (18.9–19.7)
Black, non-Hispanic 13,772 15.1 (13.9–16.4) 23.0 (21.5–24.6) 3.0 (2.5–3.7) 31.7 (29.9–33.6) 27.2 (25.6–28.8)
Hispanic 14,672 7.8 (6.9–8.7) 20.3 (18.9–21.8) 4.5 (4.0–5.1) 35.7 (33.9–37.6) 31.7 (29.9–33.5)
Other 12,154 10.7 (9.6–12.0) 19.2 (17.5–20.9) 2.9 (2.2–3.7) 35.0 (32.7–37.4) 32.2 (30.0–34.5)
Educational level
<High school 18,096 9.3 (8.4–10.3) 16.3 (15.0–17.5) 3.4 (2.9–3.9) 32.4 (30.7–34.2) 38.6 (36.8–40.5)
High school graduate 56,843 10.5 (10.0–11.0) 22.3 (21.6–23.1) 3.3 (3.0–3.7) 36.2 (35.2–37.1) 27.7 (26.9–28.6)
Some college 51,687 12.1 (11.5–12.7) 27.3 (26.4–28.2) 3.5 (3.1–3.8) 36.8 (35.9–37.8) 20.4 (19.6–21.2)
College graduate 67,814 11.0 (10.5–11.5) 30.4 (29.7–31.2) 3.3 (3.0–3.6) 39.8 (39.0–40.5) 15.6 (15.0–16.2)
Mental health symptoms†
Frequent mental distress 20,176 22.2 (21.1–23.4) 26.6 (25.2–28.0) 2.9 (2.3–3.4) 28.1 (26.6–29.6) 17.3 (16.0–18.6)
Serious psychological distress 8,010 31.4 (29.2–33.6) 26.4 (23.7–29.0) 2.3 (1.6–3.0) 22.9 (20.6–25.3) 14.4 (12.3–16.4)
Receiving medicine/treatment from a health 
professional for an emotional problem
26,279 19.3 (18.3–20.3) 27.2 (26.0–28.3) 3.2 (2.7–3.6) 29.3 (28.1–30.6) 17.6 (16.7–18.6)
None of the above 157,176 9.2 (8.9–9.5) 24.3 (23.8–24.8) 3.2 (3.0–3.5) 36.4 (35.8–36.9) 23.4 (22.9–23.9)
All of the above 3,293 51.1 (47.4–54.8) 20.7 (17.3–24.2) 2.0 (0.6–3.4) 15.6 (12.7–18.5) 9.0 (6.7–11.4)
* Attitudes were assessed by asking respondents to indicate their level of agreement with the statements “Treatment can help people with mental illness lead normal lives” and “People are 
generally caring and sympathetic to people with mental illness.”
† Adjusted for sex, age group, racial/ethnic group, education and household income level. Row totals do not equal 100% because “don’t know” and refusals were omitted. Estimates are 
weighted; sample size is unweighted.
§ Confidence intervals.
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One result from the analysis presented in this 
report was the varying attitudes by education level. 
For example, adults with greater education were more 
likely to agree strongly that mental health treatment 
can help persons with mental illness lead normal lives 
but were less likely to agree strongly that people can 
be caring and sympathetic to persons with mental 
illness. In one study, among some professionals, more 
knowledge and contact with persons with mental ill-
ness was associated with more stigmatizing attitudes 
(10). Another possibility is that these adults might 
have experienced less supportive behaviors associated 
with mental illness (i.e., feel stigmatized) and thus 
were more likely to report negative attitudes compared 
with other groups. 
in various media, and differences in awareness of 
and access to mental health treatment. Geographic 
variability in attitudes toward mental illness and its 
causes should be a topic of further study.
Attitudes toward persons with mental illness 
appear to be improving in the United States. One 
study determined that in 2006, compared with previ-
ous decades since the 1950s, more U.S. adults believed 
that mental health problems could improve with treat-
ment (8). The large proportion of adults with posi-
tive attitudes toward mental illness treatment in the 
United States (and in the 37 jurisdictions studied for 
this report) might result from antistigma campaigns, 
and greater attention, awareness, and understanding 
of mental health (9).
TABLE 3. Level of agreement* with the statement that people are caring and sympathetic to persons with mental illness,† by state and territory — 













State N % (95% CI§) %  (95% CI) %  (95% CI) %  (95% CI) %  (95% CI)
Alaska 2,365 9.4  (7.7–11.3) 25.4  (22.7–28.4) 2.3  (1.2–4.5) 37.8  (34.7–40.9) 20.3 (17.7–23.2)
Arkansas 5,299 12.7  (11.6–13.9) 27.4  (25.8–29.1) 1.4  (1.0–1.9) 33.8  (32.0–35.6) 21.6  (20.2–23.2)
California 5,052 8.0  (7.0–9.0) 21.6  (20.0–23.2) 2.1  (1.6–2.6) 42.0  (40.1–43.9) 25.1  (23.4–26.9)
Colorado 5,422 8.6  (7.7–9.6) 28.3  (26.7–29.9) 1.3  (1.0–1.6) 36.3  (34.6–38.0) 21.8  (20.2–23.4)
Connecticut 6,623 10.9  (9.8–12.0) 28.7  (27.1–30.3) 4.0  (3.3–4.7) 32.8  (31.2–34.5) 18.8  (17.5–20.1)
District of Columbia 3,419   14.3  (12.8–15.9) 28.2  (26.3–30.2) 3.0  (2.3–3.7) 30.6  (28.5–32.7) 19.5  (17.7–21.4)
Georgia 6,838  11.8  (10.7–13.0) 25.3  (23.7–26.9) 4.8  (4.1–5.7) 34.1  (32.3–35.9) 21.6  (20.1–23.1)
Hawaii 6,270 10.5  (9.4–11.7) 20.9  (19.5–22.4) 2.4  (1.9–3.0) 33.5  (31.8–35.2) 29.7  (28.0–31.4)
Illinois 5,030 10.1  (9.0–11.3) 26.8  (25.2–28.5) 1.1  (0.8–1.6) 38.4  (36.5–40.2) 22.3  (20.7–23.9)
Indiana 5,467 10.1  (9.1–11.2) 25.3  (23.7–26.9) 2.0  (1.5–2.6) 37.7  (35.8–39.6) 22.2  (20.6–23.9)
Iowa 4,921 10.5  (9.5–11.6) 25.2  (23.7–26.8) 1.5  (1.1–2.0) 40.0  (38.2–41.9) 20.3  (18.9–21.9)
Kansas 4,081 10.4  (9.3–11.6) 28.6  (26.9–30.4) 4.5  (3.7–5.3) 36.7  (34.7–38.6) 17.2  (15.7–18.8)
Kentucky 6,185  16.1  (14.6–17.7) 18.5  (17.0–20.2) 11.1  (9.8–12.7) 27.0  (25.2–28.8) 23.3  (21.6–25.1)
Louisiana 6,099  13.8  (12.6–15.1) 18.9  (17.5–20.4) 3.7  (3.1–4.4) 25.7  (24.2–27.4) 32.7  (31.1–34.4)
Maine 3,851 9.2  (8.1–10.4) 27.5  (25.7–29.5) 2.1  (1.6–2.7) 37.9  (35.9–40.0) 21.1  (19.4–22.8)
Massachusetts 4,162 11.6  (10.1–13.3) 27.1  (25.0–29.3) 3.4  (2.6–4.4) 34.7  (32.3–37.1) 20.6  (18.7–22.8)
Michigan 4,235 10.0  (8.9–11.2) 26.0  (24.2–27.8) 1.5  (0.9–2.4) 37.3  (35.3–39.3) 22.9  (21.3–24.6)
Minnesota 4,729 8.1  (7.1–9.1) 25.3  (23.6–27.0) 5.0  (4.2–6.0) 41.9  (39.9–43.9) 18.3  (16.7–20.0)
Mississippi 7,381 17.7  (16.4–19.1) 22.8  (21.5–24.2) 2.6  (2.1–3.1) 25.7  (24.2–27.2) 28.0  (26.4–29.6)
Missouri 4,850 13.2  (11.7–14.7) 29.2  (27.2–31.4) 1.5  (1.1–2.1) 36.3  (34.1–38.5) 17.8  (16.2–19.5)
Montana 5,415 9.5  (8.5–10.5) 25.5  (23.9–27.2) 4.7  (4.0–5.5) 37.8  (35.9–39.7) 17.9  (16.5–19.5)
Nebraska 4,890 8.4  (7.0–10.1) 25.7  (23.2–28.4) 2.0  (1.3–3.0) 40.7  (37.8–43.7) 19.9  (17.7–22.3)
Nevada 3,868 11.4  (10.1–12.9) 28.7  (26.4–31.0) 2.3  (1.7–3.0) 28.8  (26.6–31.1) 25.5  (23.2–27.9)
New Hampshire 5,453 10.3  (9.3–11.4) 27.5  (26.0–29.1) 3.7  (3.1–4.4) 38.6  (36.9–40.4) 17.7  (16.5–19.1)
New Mexico 5,961 10.5  (9.5–11.7) 26.1  (24.5–27.7) 2.3  (1.8–3.0) 31.7  (29.9–33.5) 25.7  (24.0–27.4)
Ohio 5,014 10.9  (9.7–12.1) 28.2  (26.5–30.0) 3.3  (2.6–4.1) 37.5  (35.6–39.4) 17.9  (16.5–19.5)
Oklahoma 6,885  11.5  (10.5–12.5) 23.6  (22.3–24.9) 1.1  (0.8–1.6) 32.7  (31.2–34.3) 27.5  (26.1–29.0)
Oregon 1,898  15.5  (13.5–17.7) 32.0  (29.2–34.8) 2.1  (1.3–3.2) 32.2  (29.5–35.0) 15.3  (13.3–17.6)
Puerto Rico 3,832 6.5  (5.5–7.6) 35.4  (33.4–37.4) 17.3 (15.7–18.9) 31.1  (29.2–33.1) 7.2  (6.2–8.3)
Rhode Island 3,923 9.4  (8.3–10.7) 23.4  (21.5–25.3) 4.5  (3.7–5.5) 39.1  (36.9–41.3) 21.8  (20.0–23.8)
South Carolina 9,889  10.9  (10.0–11.9) 24.3  (23.1–25.7) 1.2  (0.9–1.6) 35.0  (33.6–36.5) 24.2  (23.0–25.5)
Texas 7,386 10.6  (9.5–11.7) 19.8  (18.4–21.2) 5.2  (4.5–6.1) 32.1  (30.4–33.9) 26.3  (24.6–28.0)
Vermont 6,589 8.0  (7.2–8.8) 26.8  (25.4–28.3) 2.1  (1.7–2.6) 40.0  (38.4–41.6) 20.2  (18.9–21.5)
Virginia 5,305 11.0  (9.8–12.4) 28.3  (26.0–30.6) 4.2  (3.4–5.1) 36.1  (33.8–38.4) 18.3  (16.4–20.3)
Washington 13,366 17.6  (16.7–18.6) 26.8  (25.7–27.9) 3.1  (2.7–3.6) 28.1  (27.0–29.3) 19.5  (18.5–20.6)
Wisconsin 4,332 9.6  (8.3–11.0) 29.1  (27.1–31.2) 0.5  (0.3–0.9) 40.1  (37.9–42.4) 19.8  (18.1–21.6)
Wyoming 5,780 10.7  (9.7–11.8) 30.4  (28.7–32.0) 1.6  (1.2–2.0) 37.4  (35.7–39.2) 17.6  (16.3–19.0)
Total 202,065 10.6  (10.3–10.9) 24.7  (24.3–25.2) 3.2  (3.0–3.4) 35.0  (34.5.35.5) 22.3 (21.9–22.8)
* Adjusted for sex, age group, racial/ethnic group, education and household income level. Estimates are weighted; sample size is unweighted.
† Attitudes were assessed by asking respondents to indicate their level of agreement with the statement, “People are generally caring and sympathetic to people with mental illness.”
§ Confidence intervals. 
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The findings in this report are subject to at least 
four limitations. First, BRFSS surveys include only 
noninstitutionalized adults with telephones. Persons 
in institutions and in households without telephones 
are excluded, and this population might include a 
higher proportion of persons with mental health 
symptoms. Second, because states commonly use only 
English- or Spanish-language surveys, persons who 
speak other primary languages are excluded, which 
could affect race- and ethnicity-specific results. Third, 
because these data are not nationally representative, no 
conclusions can be drawn about the entire U.S. popu-
lation. Finally, the question on caring and sympathy 
requires further validation in terms of understanding 
its association with other mental health attitudinal 
measures (4).
Persons with mental illness generally are able to 
live successful, full lives, particularly if they receive 
proper treatment and support. To reduce the effects 
of stigma, public health and mental health agencies 
can implement local activities to reduce negative atti-
tudes about mental illness (3). Because the media can 
frame public opinion, they can be important partners 
in this and in promoting accounts of mental illness 
recovery (2). Public educational resources, such as 
those available on SAMHSA’s “What a difference a 
friend makes” Internet site,** also can reduce negative 
attitudes toward mental illness by providing infor-
mation about mental illness and its treatment, and 
help persons learn how to reassure, be friends with, 
and accept persons who seek or receive treatment for 
mental illness.
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On October 16, 2009, the Food and Drug 
Administra tion (FDA) licensed bivalent human papil-
lomavirus vaccine (HPV2; Cervarix, GlaxoSmithKline) 
for use in females aged 10 through 25 years. Cervarix 
is the second human papillomavirus (HPV) vac-
cine licensed for use in females in the United States. 
Quadrivalent HPV vaccine (HPV4; Gardasil, Merck & 
Co, Inc.) was licensed in 2006 for use in females aged 
9 through 26 years, and the Advisory Committee on 
Immunization Practices (ACIP) recommended routine 
HPV4 vaccination of females aged 11 or 12 years, and 
catch-up vaccination for females aged 13 through 26 
years (1). This report provides updated recommenda-
tions for routine and catch-up vaccination of females 
with either HPV2 or HPV4.
Both HPV2 and HPV4 are composed of virus-like 
particles (VLPs) prepared from recombinant L1 capsid 
protein of HPV; the two vaccines are not live vaccines 
(Table 1). HPV2 is directed against two oncogenic 
types (HPV 16 and 18). HPV4 is directed against two 
oncogenic types (HPV 16 and 18) and two nonon-
cogenic types (HPV 6 and 11). Both vaccines have 
high efficacy against HPV 16 and 18-related cervical 
precancer lesions. HPV4 also has high efficacy against 
HPV 6 and HPV 11-related genital warts and HPV 
16 and 18-related vaginal and vulvar precancer lesions 
(Table 2) (2–5).
HPV 16 and 18 cause about 70% of cervical can-
cers; each of the other oncogenic HPV types accounts 
for a small percentage of all cervical cancers. Other 
HPV-associated cancers in females include a subset 
of vulvar, vaginal, anal, and oropharyngeal and oral 
cavity cancers, caused primarily by HPV 16. HPV 6 
and 11 cause approximately 90% of genital warts and 
most cases of recurrent respiratory papillomatosis.
In anticipation of FDA licensure of HPV2, ACIP 
reviewed data on the immunogenicity, efficacy, and 
safety of HPV2, as well as information on HPV4. At 
its October 21, 2009, meeting, ACIP approved updated 
recommendations for use of HPV vaccines in females.
FDA Licensure of Bivalent Human Papillomavirus Vaccine 
(HPV2, Cervarix) for Use in Females and Updated HPV 
Vaccination Recommendations from the Advisory Committee 
on Immunization Practices (ACIP)
TABLE 1. Selected characteristics of quadrivalent human papillomavirus vaccine (HPV4) and bivalent human papillomavirus 
vaccine (HPV2)*
Characteristic HPV4 HPV2
Manufacturer Merck & Co, Inc. GlaxoSmithKline
Vaccine composition 
(L1 protein) 
20 µg HPV 6
40 µg HPV 11 20 µg HPV 16
40 µg HPV 16 20 µg HPV 18
20 µg HPV 18
Manufacturing Saccharomyces cerevisiae (bread yeast), expressing L1 Trichoplusia ni insect cell line infected with L1 encoding 
recombinant baculovirus  
Adjuvant AAHS: AS04:
225 µg amorphous aluminum hydroxyphosphate 
sulfate
500 µg aluminum hydroxide
50 µg 3-O-desacyl-4’ monophosphoryl lipid A
Preservatives None None
Other content Sodium chloride, L-histidine, polysorbate 80, sodium 
borate, and water for injection
Sodium chloride and sodium dihydrogen phosphate 
dehydrate, and water for injection
Temperature storage Store refrigerated at 36°–46°F (2°–8°C). Store refrigerated at  36°–46°F (2°–8°C).
Do not freeze. Do not freeze.
Volume per dose 0.5 mL 0.5 mL
Administration Intramuscular Intramuscular
Schedule/Intervals 3 doses
Second and third doses 1 to 2 months and 6 months 
after first dose
3 doses
Second and third doses 1 to 2 months and 6 months 
after first dose
* Both vaccines are composed of virus-like particles (VLPs) prepared from recombinant L1 capsid protein of human papillomavirus (HPV); 
the vaccines are not live vaccines.
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HPV2 Clinical Trial Data
HPV2 efficacy was evaluated in two randomized, 
double-blind, controlled clinical trials in females aged 
15 through 25 years, including a phase IIb study (6,7) 
and a phase III study (4). The phase III trial included 
18,644 females, followed for a mean of 34.9 months. 
Efficacy against HPV 16 or 18-related cervical intra-
epithelial neoplasia grade 2 or 3 or adenocarcinoma in 
situ (CIN2+) was 92.9% in the according to protocol 
analysis (Table 2) (4). Among women who were HPV 
16 or 18 DNA positive at study enrollment, the vac-
cine had no efficacy against CIN2+ due to that type. 
A subset of participants in the phase IIb study has 
been followed for up to 6.4 years (mean: 5.9 years) 
after dose one with high efficacy against HPV 16 
or 18-related CIN2+ demonstrated throughout the 
follow-up period (7).
Protection against cervical lesions due to nonvac-
cine HPV types was evaluated. In an analysis limited 
to lesions without HPV 16 or 18 coinfection, efficacy 
against CIN2+ due to any of 12 nonvaccine oncogenic 
types (HPV 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 
and 68) was 37.4% (96.1% confidence interval [CI] 
= 7.4–58.2). In a post hoc analysis, efficacy against 
HPV 31-related CIN2+ in the according to protocol 
population was 89.4% (99.7% CI = 29.0–99.7) (5).
In all studies, ≥99% of participants developed an 
HPV 16 and 18 antibody response 1 month after 
completing the 3-dose series. Bridging immunogenic-
ity studies were conducted among 1,193 females aged 
10 through 14 years; geometric mean titers (GMTs) 1 
month after the third dose were noninferior to those 
in females aged 15 through 25 years (5). The antibody 
responses for all vaccine antigens were noninferior 
after concomitant administration of HPV2 with teta-
nus toxoid, diphtheria toxoid, and acellular pertussis 
vaccine and/or with meningococcal conjugate vaccine 
in females aged 11 through 18 years compared with 
those after administration at separate visits. Rates of 
solicited and unsolicited symptoms and events were 
similar in all study groups (8).
HPV2 vaccinees were evaluated for injection-site 
and systemic symptoms, medically significant condi-
tions, new onset autoimmune disorders, new onset 
TABLE 2. Efficacy of bivalent human papillomavirus vaccine (HPV2) and quadrivalent human papillomavirus vaccine 
(HPV4) in females
Vaccine/Endpoint/HPV type
Vaccine Control Vaccine efficacy
No. Cases No. Cases %  (CI*)
Bivalent vaccine (HPV2)†  (96.1% CI)
CIN2/3 or AIS§
HPV 16 and/or 18 7,344 4 7,312 56 92.9 (79.9–98.3)
HPV 16 6,303 2 6,165 46 95.7 (82.9–99.6)
HPV 18 6,794 2 6,746 15 86.7 (39.7–98.7)
Quadrivalent vaccine (HPV4)¶ (95% CI)
CIN2/3 or AIS**
HPV 6, 11, 16, and/or 18 7,864 2 7,865 110 98.2 (93.3–99.8)
HPV 16 6,647 2 6,455 81 97.6 (91.1–99.7)
HPV 18 7,382 0 7,316 29 100.0 (86.6–100.0)
VIN2/3 or VaIN2/3 **
HPV 6, 11, 16, and/or 18   7,900         0 7,902 23 100.0 (82.6–100.0)
HPV 16  6,654 0 6,467 17 100.0 (76.5–100.0)
HPV 18 7,414 0 7,343 2 100.0 (<0–100.0)
Genital warts††
HPV 6 and/or 11 6,932 2 6,856 189 99.0 (96.2–99.9)
Abbreviations: CIN2/3 = cervical intraepithelial neoplasia grade 2 or 3, AIS = adenocarcinoma in situ, VIN2/3 = vulvar intraepithelial neopla-
sia grade 2 or 3, VaIN2/3 = vaginal intraepithelial neoplasia grade 2 or 3, HPV = human papillomavirus.
 * Confidence interval.
 † Phase III trial.  According to protocol efficacy analysis included females aged 15 through 25 years who received all 3 vaccine doses, were 
seronegative at day 1 and HPV DNA negative at day 1 through month 6 for the respective HPV type, and had normal or low grade cytology 
at day 1, with case counting beginning 1 day after third vaccine dose; mean duration of follow-up post first vaccine dose: 34.9 months.
 § Source: Paavonen J, Naud P, Salmeron J, et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and 
precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 2009;374:301–14.
 ¶ Combined analysis of one phase II and two phase III trials.  Per protocol efficacy analysis included females aged 16 through 26 years who 
received all 3 vaccine doses, were seronegative at day 1 and HPV DNA negative at day 1 through month 7 for the respective HPV type, 
with case counting beginning 1 month after third vaccine dose; mean duration of follow-up post first vaccine dose: 42 months.
 ** Source: Kjaer SK, Sigurdsson K, Iversen OE, et al. A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus 
(Types 6/11/16/18) vaccine against high-grade cervical and external genital lesions. Cancer Prev Res 2009;2:868–78.
 †† Source: Food and Drug Administration. Product approval-prescribing information [package insert]. Gardasil [human papillomavirus qua-
drivalent (types 6, 11, 16, and 18) vaccine, recombinant], Merck & Co, Inc: Food and Drug Administration 2009. Available at http://www.
fda.gov/biologicsbloodvaccines/vaccines/approvedproducts/ucm094042.htm. Accessed May 25, 2010.
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chronic diseases, deaths, serious adverse events, and 
pregnancy outcomes. Safety was evaluated by pooling 
data from 11 clinical trials of bivalent vaccine in females 
aged 10 through 25 years (9), and by a meta-analysis 
of safety databases of bivalent vaccine as well as other 
vaccines with the same adjuvant (10). The pooled safety 
analysis included 23,713 females aged 10 through 25 
years; approximately 12,000 females received at least 
1 dose of HPV2. In an analysis of local and general 
adverse events, a larger proportion of persons reported 
at least one injection-site symptom in the HPV2 group 
compared with controls (5). In the HPV2 group, 92% 
reported injection-site pain, 48% redness, and 44% 
swelling compared with 64%–87%, 24%–28%, and 
17%–21% in the control groups. Fatigue, headache, 
and myalgia were the most common general symptoms. 
No differences were observed in unsolicited symptoms 
within 30 days of vaccination between the vaccine 
group and control groups. 
Serious adverse events and deaths were evaluated in 
a pooled safety analysis that included 29,953 females 
aged 10 through 72 years (16,142 received HPV2). 
Proportions of persons reporting a serious adverse event 
were similar in vaccine and control groups (5.3% and 
5.9%, respectively), as were the types of serious adverse 
events reported (5). In the pooled safety analysis, includ-
ing 12,533 women who received HPV2 and over 10,730 
in the control groups, incidence of potential new autoim-
mune disorders did not differ (0.8% in both groups).
Clinical protocols excluded women who were 
pregnant, and participants were instructed to avoid 
pregnancy until 2 months after the last vaccination. 
However, 3,696 pregnancies occurred in the vaccine 
group and 3,580 in the pooled control groups. Overall, 
no differences were observed in rates of any specific 
pregnancy outcomes between groups (5). Among 761 
pregnancies around the time of vaccination (defined 
as last menstrual period 30 days before to 45 days 
after vaccination), 13.6% of pregnancies ended in 
spontaneous abortion in the vaccine group compared 
with 9.6% in the control group. HPV2 has been clas-
sified as Category B on the basis of animal studies that 
revealed no evidence of impaired fertility or harm to 
the fetus. No data are available on use of HPV2 in 
lactating women.
Vaccine Recommendations for HPV2 
and HPV4
ACIP recommends routine vaccination of females 
aged 11 or 12 years with 3 doses of either HPV2 or 
HPV4. The vaccination series can be started begin-
ning at age 9 years.
Vaccination is recommended for females aged 
13 through 26 years who have not been vaccinated 
previously or who have not completed the 3-dose 
series. If a female reaches age 26 years before the 
vaccination series is complete, remaining doses can 
be administered after age 26 years. Ideally, vaccine 
should be administered before potential exposure to 
HPV through sexual contact.
ACIP recommends vaccination with HPV2 or 
HPV4 for prevention of cervical cancers and precan-
cers. Both vaccines might provide protection against 
some other HPV-related cancers in addition to cer-
vical cancer, although there are currently only data 
sufficient to recommend HPV4 for protection against 
vulvar and vaginal cancers and precancers. HPV4 is 
recommended also for prevention of genital warts.
Dosage, Administration, and Schedules
The dosing and administration schedules are 
the same for HPV4 and HPV2. Each dose is 0.5 
mL, administered intramuscularly, preferably in a 
deltoid muscle. The vaccines are administered in a 
3-dose schedule. The second dose is administered 1 
to 2 months after the first dose, and the third dose is 
administered 6 months after the first dose.
The minimum interval between the first and sec-
ond dose of vaccine is 4 weeks and between the second 
and third dose is 12 weeks. The minimum interval 
between the first and third dose is 24 weeks. Doses 
received after a shorter-than-recommended dosing 
interval should be readministered. If the HPV vaccine 
schedule is interrupted, the vaccine series does not 
need to be restarted. Coadministration of a different 
inactivated or live vaccine, either simultaneously or 
at any time before or after HPV vaccine, is permitted 
because neither HPV vaccine is a live vaccine.
Whenever feasible, the same HPV vaccine should 
be used for the entire vaccination series. No studies 
address interchangeability of HPV vaccines. However, 
if the vaccine provider does not know or have available 
the HPV vaccine product previously administered, 
either HPV vaccine can be used to complete the series 
to provide protection against HPV 16 and 18. For 
protection against HPV 6 or 11-related genital warts, 
a vaccination series with less than 3 doses of HPV4 
might provide less protection against genital warts 
than a complete 3-dose HPV4 series.
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Special Situations
Females who have abnormalities on their cervical 
cancer screening results are likely to be infected with 
one or more genital HPV types. With increasing sever-
ity of Papanicolau (Pap) findings, the likelihood of 
infection with HPV 16 or 18 increases, and benefits 
of vaccination decrease. Vaccination is still recom-
mended for such females, because vaccination can 
provide protection against infection with HPV vaccine 
types not already acquired. Females should be advised 
that vaccination will have no therapeutic effect on an 
existing HPV infection or abnormal Pap test.
Prevaccination assessments (e.g., Pap testing or 
screening for high-risk HPV DNA, type-specific HPV 
tests, or HPV antibody) to establish the appropriateness 
of HPV vaccination are not recommended at any age.
A history of genital warts or clinically evident 
genital warts indicates infection with HPV, most often 
HPV 6 or 11. Vaccination is still recommended for 
such females because vaccination can provide protec-
tion against infection with HPV vaccine types not 
already acquired. Females should be advised that vac-
cination will have no therapeutic effect on an existing 
HPV infection or genital warts.
Lactating women can receive HPV vaccine.
HPV2 and HPV4 are not live vaccines, and can be 
administered to females who are immunosuppressed 
(from disease or medications). However, the immune 
response and vaccine efficacy might be less than that 
in immunocompetent persons.
Precautions and Contraindications
HPV vaccines are not recommended for use in 
pregnant women. If a woman is found to be pregnant 
after initiating the vaccination series, the remainder of 
the 3-dose series should be delayed until completion 
of pregnancy. Pregnancy testing is not needed before 
vaccination. If a vaccine dose has been administered 
during pregnancy, no intervention is needed.
Patients and health-care providers should report 
any exposure to HPV4 during pregnancy to Merck at 
telephone, 800-986-8999, and any exposure to HPV2 
during pregnancy to GlaxoSmithKline at telephone, 
888-452-9622.
HPV vaccines can be administered to persons with 
minor acute illnesses. Vaccination of persons with 
moderate or severe acute illnesses should be deferred 
until after the patient improves.
Syncope can occur after vaccination and has been 
observed among adolescents and young adults. To 
avoid serious injury related to a syncopal episode, 
vaccine providers should consider observing patients 
for 15 minutes after they are vaccinated.
HPV vaccines are contraindicated for persons with 
a history of immediate hypersensitivity to any vaccine 
component. HPV4 is produced in Saccharomyces 
cerevisiae (baker’s yeast) and is contraindicated for 
persons with a history of immediate hypersensitivity 
to yeast. Prefilled syringes of HPV2 have latex in the 
rubber stopper and should not be used in persons 
with anaphylactic latex allergy. HPV2 single dose 
vials contain no latex.
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day 1 through month 7 to the respective HPV type 
(per protocol population) was 89.4%; the efficacy for 
HPV 6 or 11-related genital warts alone was approxi-
mately the same (Table) (5). The efficacy for preven-
tion of HPV 6, 11, 16, or 18-related genital warts 
among males who received at least 1 vaccine dose 
and regardless of baseline DNA or serology (intent 
to treat population), was 67.2%, and the efficacy for 
prevention of genital warts related to any HPV type 
was 62.1% (Table) (5). No evidence of efficacy was 
observed among males who were infected with the 
respective HPV type at baseline. The median duration 
of follow-up at the time of the study’s interim analysis 
was approximately 2.3 years.
Data on immunogenicity in males are available 
from the phase III trial conducted among males aged 
16 through 26 years, and from bridging immunoge-
nicity studies conducted among males aged 9 through 
15 years (5). Seroconversion rates were high for all 
four HPV types (HPV 6, 11, 16, or 18) targeted 
by HPV4, and postvaccination antibody titers were 
significantly higher in males aged 9 through 15 years 
compared with males aged 16 through 26 years (5).
As observed previously with females, in the clini-
cal trials for males, the most common adverse events 
were injection-site reactions, most of which were mild 
or moderate in intensity (5). Headache and fever 
were the most commonly reported systemic adverse 
reactions in both treatment groups (5). Postlicensure 
data in females indicate that HPV4 adverse events are 
similar to adverse events reported following adminis-
tration of other vaccines to adolescents (6).
Mathematical modeling suggests that adding male 
HPV vaccination to a female-only HPV vaccination 
program is not the most cost-effective vaccination 
strategy for reducing the overall burden of HPV-
associated conditions in males and females when 
vaccination coverage of females is high (>80%) (7). 
When coverage of females is less than 80%, male vac-
cination might be cost-effective, although results vary 
substantially across models (7). Because the health 
burden is greater in females than males, and numer-
ous models have shown vaccination of adolescent girls 
to be a cost-effective use of public health resources, 
On October 16, 2009, the Food and Drug 
Administration licensed quadrivalent human pap-
illomavirus vaccine (HPV4; Gardasil, Merck & 
Co. Inc.) for use in males aged 9 through 26 years 
for prevention of genital warts caused by human 
papillomavirus (HPV) types 6 and 11. HPV4 had 
been licensed previously for use in females aged 9 
through 26 years for prevention of HPV 6, 11, 16, 
and 18-related outcomes (i.e., vaginal, vulvar, and 
cervical precancers and cancers and genital warts). 
The Advisory Committee on Immunization Practices 
(ACIP) recommends routine vaccination of females 
at age 11 or 12 years and catch-up vaccination for 
females aged 13 through 26 years (1). On October 
21, 2009, ACIP provided guidance that HPV4 may 
be given to males aged 9 through 26 years to reduce 
their likelihood of acquiring genital warts; ACIP does 
not recommend HPV4 for routine use among males. 
This report presents the ACIP policy statement and 
summarizes background data. Issues reviewed by 
ACIP included efficacy, immunogenicity, and safety 
of the HPV4 vaccine in males, epidemiology of HPV 
and burden of HPV-associated diseases and cancers 
in males, cost-effectiveness of male vaccination, and 
programmatic considerations.
HPV types 6 and 11 cause approximately 90% 
of genital warts and most cases of recurrent respira-
tory papillomatosis. Approximately 500,000 cases of 
genital warts are estimated to occur each year in the 
United States among sexually active men and women 
(2,3). Direct medical costs related to genital warts are 
estimated at $200 million per year (2,3); in addition, 
genital warts can have an adverse impact on quality 
of life (4). HPV-associated cancers in males include 
certain anal, penile, and oropharyngeal and oral cavity 
cancers caused primarily by HPV 16.
HPV4 has high efficacy for prevention of genital 
warts. The phase III efficacy study enrolled 4,065 
males aged 16 through 26 years. Participants were 
enrolled from North America, South America, 
Europe, Australia, and Asia. The efficacy for preven-
tion of genital warts related to HPV types 6, 11, 16, 
or 18 among males who received all 3 vaccine doses 
and were seronegative at day 1, and DNA negative 
FDA Licensure of Quadrivalent Human Papillomavirus Vaccine 
(HPV4, Gardasil) for Use in Males and Guidance from the Advisory 
Committee on Immunization Practices (ACIP)
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improving coverage in females aged 11 and 12 years 
could potentially be a more effective and cost-effective 
strategy than adding male vaccination.
Men who have sex with men (MSM) are par-
ticularly at risk for conditions associated with HPV 
types 6, 11, 16, and 18; diseases and cancers that 
have a higher incidence among MSM include anal 
intraepithelial neoplasias, anal cancers, and genital 
warts (8,9). HPV4 has high efficacy for prevention of 
anal intraepithelial neoplasias in MSM (10); however, 
this information was not available before the October 
2009 ACIP meeting and has not yet been reviewed 
by FDA.
Vaccine Guidance
The 3-dose series of HPV4 may be given to males 
aged 9 through 26 years to reduce their likelihood of 
acquiring genital warts. HPV4 would be most effec-
tive when given before exposure to HPV through 
sexual contact.
Administration, Special Situations, 
Precautions, and Contraindications
HPV4 is administered in a 3-dose schedule. The 
second dose is administered 1 to 2 months after the 
first dose, and the third dose is administered 6 months 
after the first dose. The minimum interval between 
the first and second dose of vaccine is 4 weeks, and 
the minimum interval between the second and third 
dose is 12 weeks. The minimum interval between the 
first and third dose is 24 weeks. Doses received after 
a dosing interval that is shorter than recommended 
should be readministered.
If the HPV vaccine schedule is interrupted, 
the vaccine series does not need to be restarted. 
Coadministration of a different inactivated or live 
vaccine, either simultaneously or at any time before 
or after HPV4 is permitted because HPV4 is not a 
live vaccine.
HPV4 can be administered to persons who are 
immunosuppressed (from disease or medications). 
However, the immune response and vaccine efficacy 
might be less than that in immunocompetent persons.
HPV4 can be administered to persons with minor 
acute illnesses. Vaccination of persons with moderate 
or severe acute illnesses should be deferred until after 
the patient improves.
Syncope can occur after vaccination and has been 
observed among adolescents and young adults. To 
avoid serious injury related to a syncopal episode, 
vaccine providers should consider observing patients 
for 15 minutes after they are vaccinated.
HPV4 is contraindicated for persons with a history 
of immediate hypersensitivity to any vaccine com-
ponent. HPV4 is a recombinant vaccine produced 
in Saccharomyces cerevisiae (baker’s yeast) and is con-
traindicated for persons with a history of immediate 
hypersensitivity to yeast.
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Announcement
State-Specific Health-Care–Associated 
Infections Summary Data Report
CDC’s Division of Healthcare Quality Promotion 
has published the first state-specific health-care–
associated infections (HAIs) summary data report. This 
report includes data reported by health-care facilities 
to CDC’s National Healthcare Safety Network 
(NHSN), a public health surveillance system that 
serves as a mainstay of HAI monitoring and prevention 
programs.
This initial report presents state-specific data for cen-
tral line–associated bloodstream infections (CLABSIs) 
in states requiring facilities to report CLABSIs through 
NHSN, and overall national data. The standardized 
infection ratio is used to compare data reported to 
NHSN from January–June 2009 with the national 
NHSN data from 2006–2008. This report provides 
baseline measurements that can guide state prevention 
activities. In addition, this report represents a first step 
in monitoring national progress toward the CLABSI 
prevention goals in the U.S. Department of Health 
and Human Services Action Plan to Prevent Healthcare-
Associated Infections. The full CDC report is available at 
http://www.cdc.gov/hai/statesummary.html.
Notice to Readers
NNDSS Tables Have Updated “N” Indicators 
for the Year 2009
The 2009 Council of State and Territorial 
Epidemiologists (CSTE) State Reportable Conditions 
Assessment (2009 SRCA) has collected data from 55 
reporting jurisdictions (50 U.S. states, the District of 
Columbia, New York City, and three U.S. territories) 
to determine which of the nationally notifiable condi-
tions (NNC) were reportable in each reporting juris-
diction during 2009. The 2009 SRCA gathered infor-
mation regarding whether the condition is explicitly 
reportable (i.e., listed as a specific disease or as a cat-
egory of diseases on reportable disease lists), whether 
a condition is implicitly reportable (i.e., included in 
a general category of the reportable disease list, such 
as “rare diseases of public health importance”), or not 
reportable within each jurisdiction. Only conditions 
that were explicitly reportable were considered report-
able under 2009 SRCA methodology.
Results of the 2009 SRCA will be used to indicate 
whether each NNC is or is not reportable for the 
specified period and reporting jurisdiction. NNC 
that are not reportable are noted with an “N” indi-
cator (for “not reportable”) in the MMWR Table II 
weekly update (Provisional cases of selected notifiable 
diseases, United States) and in the MMWR Summary 
of Notifiable Diseases — United States, 2009. This 
notation will allow readers to distinguish whether 1) 
no cases were reported even though the condition is 
reportable or 2) no cases were reported because the 
condition is not reportable.
The 2009 SRCA data collection and validation 
concluded in May 2010; results will be used to popu-
late the “N” indicators for NNDSS data in both 2009 
and 2010 MMWR data tables. The 2009 NNDSS 
data displayed in the MMWR weekly provisional 
tables will reflect reporting requirements gathered 
from the 2009 SRCA until 2010 SRCA official results 
are available.
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QuickStats 
FROM THE NATIONAL CENTER FOR HEALTH STATISTICS
Percentage of Children Aged <18 Years with an Impairment or Health 
Problem That Limits Crawling, Walking, Running, or Playing, by Age 
Group and Poverty Status* — National Health Interview Survey (NHIS), 
United States, 2001–2007†
* For each survey year, poverty status is based on the ratio of the family’s income to federal poverty levels, as 
calculated by the U.S. Census Bureau. In addition to family income, federal poverty levels take into account 
family size and the number of children in the family. A larger ratio of income relative to poverty level indicates 
increasing family income and thus decreasing poverty status. Because of high levels of missing income data in 
NHIS, poverty status was determined from the 2001–2007 NHIS multiple imputed income and earnings data 
files. 
† Estimates are based on household interviews of a sample of the civilian, noninstitutionalized U.S. population. 
One child aged <18 years was randomly selected per family; a knowledgeable adult provided information for 
each child. Prevalence of impairments or health problems resulting in activity limitations is based on a ques-
tion that asked, “Does [the sample child] have an impairment or health problem that limits [his/her] ability to 
crawl, walk, run, or play?” Unknowns with respect to impairments are excluded from the denominators. 
§ 95% confidence interval. 
During 2001–2007, children aged 12–17 years were more likely than younger children to have an impairment or health prob-
lem that limited crawling, walking, running, or playing. The prevalence of such impairments or problems generally declined as 
poverty status decreased. 
Source: National Health Interview Survey, 2001–2007, sample child core component. Available at http://www.cdc.gov/nchs/nhis/quest_data_ 
related_1997_forward.htm.
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TABLE I. Provisional cases of infrequently reported notifiable diseases (<1,000 cases reported during the preceding year) — United States, week ending 









Total cases reported 
for previous years States reporting cases 
during current week (No.)2009 2008 2007 2006 2005
Anthrax — — — 1 — 1 1 —
Botulism, total 1 23 3 116 145 144 165 135
 foodborne — 3 0 11 17 32 20 19
 infant 1 18 2 80 109 85 97 85 OK (1)
 other (wound and unspecified) — 2 0 25 19 27 48 31
Brucellosis — 31 3 115 80 131 121 120
Chancroid — 21 0 33 25 23 33 17
Cholera — 2 0 10 5 7 9 8
Cyclosporiasis§ 1 27 17 141 139 93 137 543 TX (1)
Diphtheria — — — — — — — —
Domestic arboviral diseases § ,¶:
 California serogroup virus disease — — 0 55 62 55 67 80
 Eastern equine encephalitis virus disease — — — 4 4 4 8 21
 Powassan virus disease — — 0 6 2 7 1 1
 St. Louis encephalitis virus disease — — 0 12 13 9 10 13
 Western equine encephalitis virus disease — — — — — — — —
Haemophilus influenzae,** invasive disease (age <5 yrs):
 serotype b — 7 0 35 30 22 29 9
 nonserotype b — 67 4 236 244 199 175 135
 unknown serotype 2 89 4 180 163 180 179 217 NY (1), SC (1)
Hansen disease§ — 15 1 81 80 101 66 87
Hantavirus pulmonary syndrome§ — 2 1 14 18 32 40 26
Hemolytic uremic syndrome, postdiarrheal§ — 40 4 240 330 292 288 221
HIV infection, pediatric (age <13 yrs)†† — — 1 — — — — 380
Influenza-associated pediatric mortality§,§§ 3 51 2 360 90 77 43 45 GA (1), TX (2)
Listeriosis 10 186 10 858 759 808 884 896 NY (1), PA (1), OH (1), FL (2), WA (1), CA (4)
Measles¶¶ 3 22 3 67 140 43 55 66 NE (3)
Meningococcal disease, invasive***:
 A, C, Y, and W-135 2 101 6 287 330 325 318 297 TX (1), WA (1)
 serogroup B — 42 3 164 188 167 193 156
 other serogroup — 5 1 23 38 35 32 27
 unknown serogroup 3 162 12 502 616 550 651 765 MO (1), FL (1), KY (1)
Mumps 85 1,457 81 2,069 454 800 6,584 314 NY (3), NYC (71), OH (1), IA (2), NE (1), TX (3), WA (2), CA (2)
Novel influenza A virus infections††† — — 0 43,771 2 4 NN NN
Plague — — 0 8 3 7 17 8
Poliomyelitis, paralytic — — — 1 — — — 1
Polio virus Infection, nonparalytic§ — — — — — — NN NN
Psittacosis§ — 4 0 9 8 12 21 16
Q fever, total§,§§§ 3 26 3 110 120 171 169 136
 acute 3 19 2 90 106 — — — NY (1), CA (2)
 chronic — 7 0 20 14 — — —
Rabies, human — — — 3 2 1 3 2
Rubella¶¶¶ 1 2 0 3 16 12 11 11 WA (1)
Rubella, congenital syndrome — — 0 1 — — 1 1
SARS-CoV§,**** — — — — — — — —
Smallpox§ — — — — — — — —
Streptococcal toxic-shock syndrome§ 2 66 3 161 157 132 125 129 NY (1), KY (1)
Syphilis, congenital (age <1 yr)†††† — 59 7 422 431 430 349 329
Tetanus — — 0 18 19 28 41 27
Toxic-shock syndrome (staphylococcal)§ 2 32 1 78 71 92 101 90 CA (2)
Trichinellosis — 1 0 12 39 5 15 16
Tularemia 2 8 3 93 123 137 95 154 MO (1), OK (1)
Typhoid fever 7 129 7 401 449 434 353 324 PA (1), VA (1), WA (1), CA (4)
Vancomycin-intermediate Staphylococcus aureus§ — 22 1 78 63 37 6 2
Vancomycin-resistant Staphylococcus aureus§ — 1 — — — 2 1 3
Vibriosis (noncholera Vibrio species infections)§ 11 78 5 798 588 549 NN NN MD (1), VA (1), FL (5), OK (1), AZ (1), CA (2)
Viral hemorrhagic fever§§§§ — 1 — NN NN NN NN NN
Yellow fever — — — — — — — —
See Table I footnotes on next page.
Notifiable Diseases and Mortality Tables
MMWR  Morbidity and Mortality Weekly Report
 MMWR  /  May 28, 2010  /  Vol. 59  /  No. 20 635 
Notifiable Disease Data Team and 122 Cities Mortality Data Team
 Patsy A. Hall-Baker
Deborah A. Adams  Rosaline Dhara
Willie J. Anderson  Pearl C. Sharp
Jose Aponte  Michael S. Wodajo
Lenee Blanton
* Ratio of current 4-week total to mean of 15 4-week totals (from previous, comparable, and subsequent 4-week periods for the 
past 5 years). The point where the hatched area begins is based on the mean and two standard deviations of these 4-week 
totals.
FIGURE I. Selected notifiable disease reports, United States, comparison of provisional 4-week 


























TABLE I. (Continued) Provisional cases of infrequently reported notifiable diseases (<1,000 cases reported during the preceding year) — United States, week 
ending May 22, 2010 (20th week)*
—: No reported cases. N: Not reportable. NN: Not Nationally Notifiable Cum: Cumulative year-to-date counts.
 * Incidence data for reporting years 2009 and 2010 are provisional, whereas data for 2005 through 2008 are finalized.
 † Calculated by summing the incidence counts for the current week, the 2 weeks preceding the current week, and the 2 weeks following the current week, for a total of 5 preceding years. 
Additional information is available at http://www.cdc.gov/ncphi/disss/nndss/phs/files/5yearweeklyaverage.pdf.
 § Not reportable in all states. Data from states where the condition is not reportable are excluded from this table, except starting in 2007 for the domestic arboviral diseases and influenza-
associated pediatric mortality, and in 2003 for SARS-CoV. Reporting exceptions are available at http://www.cdc.gov/ncphi/disss/nndss/phs/infdis.htm.
 ¶ Includes both neuroinvasive and nonneuroinvasive. Updated weekly from reports to the Division of Vector-Borne Infectious Diseases, National Center for Zoonotic, Vector-Borne, and 
Enteric Diseases (ArboNET Surveillance). Data for West Nile virus are available in Table II.
 ** Data for H. influenzae (all ages, all serotypes) are available in Table II.
 †† Updated monthly from reports to the Division of HIV/AIDS Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention. Implementation of HIV reporting influences 
the number of cases reported. Updates of pediatric HIV data have been temporarily suspended until upgrading of the national HIV/AIDS surveillance data management system is 
completed. Data for HIV/AIDS, when available, are displayed in Table IV, which appears quarterly.
 §§ Updated weekly from reports to the Influenza Division, National Center for Immunization and Respiratory Diseases. Since April 26, 2009, a total of 285 influenza-associated pediatric 
deaths associated with 2009 influenza A (H1N1) virus infection have been reported. Since August 30, 2009, a total of 276 influenza-associated pediatric deaths occurring during the 
2009–10 influenza season have been reported. A total of 134 influenza-associated pediatric deaths occurring during the 2008-09 influenza season have been reported.
 ¶¶ The three measles cases reported for the current week were indigenous.
 *** Data for meningococcal disease (all serogroups) are available in Table II.
 ††† CDC discontinued reporting of individual confirmed and probable cases of 2009 pandemic influenza A (H1N1) virus infections on July 24, 2009. CDC will report the total number of 2009 
pandemic influenza A (H1N1) hospitalizations and deaths weekly on the CDC H1N1 influenza website (http://www.cdc.gov/h1n1flu). In addition, three cases of novel influenza A virus 
infections, unrelated to the 2009 pandemic influenza A (H1N1) virus, were reported to CDC during 2009.
 §§§ In 2009, Q fever acute and chronic reporting categories were recognized as a result of revisions to the Q fever case definition. Prior to that time, case counts were not differentiated with 
respect to acute and chronic Q fever cases.
 ¶¶¶ The one rubella case reported for the current week was indigenous.
 **** Updated weekly from reports to the Division of Viral and Rickettsial Diseases, National Center for Zoonotic, Vector-Borne, and Enteric Diseases.
 †††† Updated weekly from reports to the Division of STD Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention.
 §§§§ There was one case of viral hemorrhagic fever reported during week 12. The one case report was confirmed as lassa fever. See Table II for dengue hemorrhagic fever.
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TABLE II. Provisional cases of selected notifiable diseases, United States, weeks ending May 22, 2010, and May 23, 2009 (20th week)*
Reporting area
Chlamydia trachomatis infection Cryptosporidiosis
Current  
week






Previous 52 weeks Cum  
2010
Cum  
2009Med Max Med Max
United States 10,705 23,120 27,343 372,635 485,348 59 122 284 1,765 1,868
New England 972 739 1,396 14,151 15,445 4 5 30 95 138
Connecticut 238 213 736 3,393 4,457 — 0 26 26 38
Maine† 37 49 75 953 1,004 1 1 4 21 13
Massachusetts 510 383 767 7,664 7,321 — 1 15 — 39
New Hampshire 94 35 60 356 819 — 2 6 21 20
Rhode Island† 67 70 130 1,346 1,370 — 0 8 8 2
Vermont† 26 23 63 439 474 3 1 9 19 26
Mid. Atlantic 3,072 3,105 4,619 64,160 61,741 5 14 38 210 225
New Jersey 427 441 624 8,438 9,859 — 0 5 — 13
New York (Upstate) 739 632 2,530 12,723 11,392 2 3 16 48 50
New York City 1,326 1,182 2,283 25,521 23,353 — 1 5 17 35
Pennsylvania 580 850 1,056 17,478 17,137 3 9 19 145 127
E.N. Central 865 3,462 4,413 41,037 80,275 6 29 73 364 457
Illinois — 1,061 1,322 146 24,549 — 3 8 54 44
Indiana — 324 602 4,511 9,210 — 4 11 40 101
Michigan 729 885 1,412 19,306 18,749 — 6 11 102 84
Ohio 136 920 1,039 14,280 19,212 6 7 16 126 115
Wisconsin — 370 466 2,794 8,555 — 8 39 42 113
W.N. Central 60 1,308 1,711 22,309 27,952 11 19 59 275 246
Iowa 11 180 252 3,825 3,907 2 4 13 65 62
Kansas — 172 571 2,745 4,067 1 2 6 29 25
Minnesota — 263 337 4,661 5,776 4 5 31 94 47
Missouri — 492 638 8,613 10,310 2 3 12 44 47
Nebraska† 49 93 237 1,835 2,047 2 2 9 34 25
North Dakota — 31 93 630 658 — 0 18 3 1
South Dakota — 49 82 — 1,187 — 1 10 6 39
S. Atlantic 2,010 4,428 6,098 63,585 99,415 14 20 50 335 316
Delaware 68 88 145 1,657 1,878 — 0 2 1 —
District of Columbia — 112 178 1,610 2,773 — 0 1 2 3
Florida 630 1,399 1,669 27,198 29,145 5 8 24 133 100
Georgia 9 508 1,323 2,065 16,562 5 6 31 132 124
Maryland† — 444 1,031 7,387 8,618 1 1 3 11 18
North Carolina — 678 1,291 — 16,496 — 1 11 11 27
South Carolina† 628 521 1,331 10,543 10,738 — 1 7 15 18
Virginia† 606 600 924 11,689 11,639 2 1 7 24 21
West Virginia 69 65 137 1,436 1,566 1 0 2 6 5
E.S. Central 979 1,654 2,264 29,822 35,570 1 4 13 66 60
Alabama† 398 465 606 9,083 10,152 — 1 5 21 18
Kentucky — 290 642 5,032 4,108 — 2 4 22 14
Mississippi — 429 640 5,966 9,572 — 0 6 4 9
Tennessee† 581 557 734 9,741 11,738 1 1 5 19 19
W.S. Central 585 2,949 5,784 52,993 61,884 6 8 40 97 90
Arkansas† 322 271 402 5,815 5,780 — 1 5 12 10
Louisiana — 390 1,055 2,922 11,678 1 1 6 14 9
Oklahoma 263 247 2,727 5,904 2,776 3 2 9 17 25
Texas† — 2,041 3,229 38,352 41,650 2 5 30 54 46
Mountain 511 1,451 2,118 22,713 27,336 3 10 25 156 138
Arizona 141 467 713 4,827 9,946 — 0 3 10 13
Colorado — 433 709 6,699 4,104 — 2 10 47 32
Idaho† 108 61 185 1,046 1,387 — 2 7 27 17
Montana† 13 56 74 1,148 1,283 2 1 4 20 13
Nevada† 158 173 478 3,662 4,122 — 0 2 5 7
New Mexico† — 169 453 2,213 3,173 — 2 8 23 38
Utah 76 115 174 2,378 2,532 — 1 4 17 6
Wyoming† 15 36 70 740 789 1 0 2 7 12
Pacific 1,651 3,454 5,313 61,865 75,730 9 13 27 167 198
Alaska — 103 144 2,247 2,157 — 0 1 1 2
California 1,404 2,651 4,406 48,460 57,937 8 8 20 100 102
Hawaii — 113 137 1,779 2,443 — 0 0 — 1
Oregon — 180 468 1,367 4,270 1 3 10 44 71
Washington 247 397 638 8,012 8,923 — 1 8 22 22
American Samoa — 0 0 — — N 0 0 N N
C.N.M.I. — — — — — — — — — —
Guam — 1 27 78 — — 0 0 — —
Puerto Rico — 118 329 2,125 2,873 N 0 0 N N
U.S. Virgin Islands — 9 21 52 201 — 0 0 — —
C.N.M.I.: Commonwealth of Northern Mariana Islands.
U: Unavailable.   —: No reported cases.   N: Not reportable.   NN: Not Nationally Notifiable.   Cum: Cumulative year-to-date counts.   Med: Median.   Max: Maximum.
* Incidence data for reporting years 2009 and 2010 are provisional. Data for HIV/AIDS, AIDS, and TB, when available, are displayed in Table IV, which appears quarterly.
† Contains data reported through the National Electronic Disease Surveillance System (NEDSS).
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TABLE II. (Continued) Provisional cases of selected notifiable diseases, United States, weeks ending May 22, 2010, and May 23, 2009 (20th week)*
Dengue Virus Infection
Reporting area
Dengue Fever Dengue Hemorrhagic Fever†
Current  
week






Previous 52 weeks Cum  
2010
Cum  
2009Med Max Med Max
United States — 0 1 3 NN — 0 0 — NN
New England — 0 1 2 NN — 0 0 — NN
Connecticut — 0 0 — NN — 0 0 — NN
Maine§ — 0 1 2 NN — 0 0 — NN
Massachusetts — 0 0 — NN — 0 0 — NN
New Hampshire — 0 0 — NN — 0 0 — NN
Rhode Island§ — 0 0 — NN — 0 0 — NN
Vermont§ — 0 0 — NN — 0 0 — NN
Mid. Atlantic — 0 1 1 NN — 0 0 — NN
New Jersey — 0 0 — NN — 0 0 — NN
New York (Upstate) — 0 0 — NN — 0 0 — NN
New York City — 0 0 — NN — 0 0 — NN
Pennsylvania — 0 1 1 NN — 0 0 — NN
E.N. Central — 0 0 — NN — 0 0 — NN
Illinois — 0 0 — NN — 0 0 — NN
Indiana — 0 0 — NN — 0 0 — NN
Michigan — 0 0 — NN — 0 0 — NN
Ohio — 0 0 — NN — 0 0 — NN
Wisconsin — 0 0 — NN — 0 0 — NN
W.N. Central — 0 0 — NN — 0 0 — NN
Iowa — 0 0 — NN — 0 0 — NN
Kansas — 0 0 — NN — 0 0 — NN
Minnesota — 0 0 — NN — 0 0 — NN
Missouri — 0 0 — NN — 0 0 — NN
Nebraska§ — 0 0 — NN — 0 0 — NN
North Dakota — 0 0 — NN — 0 0 — NN
South Dakota — 0 0 — NN — 0 0 — NN
S. Atlantic — 0 0 — NN — 0 0 — NN
Delaware — 0 0 — NN — 0 0 — NN
District of Columbia — 0 0 — NN — 0 0 — NN
Florida — 0 0 — NN — 0 0 — NN
Georgia — 0 0 — NN — 0 0 — NN
Maryland§ — 0 0 — NN — 0 0 — NN
North Carolina — 0 0 — NN — 0 0 — NN
South Carolina§ — 0 0 — NN — 0 0 — NN
Virginia§ — 0 0 — NN — 0 0 — NN
West Virginia — 0 0 — NN — 0 0 — NN
E.S. Central — 0 0 — NN — 0 0 — NN
Alabama§ — 0 0 — NN — 0 0 — NN
Kentucky — 0 0 — NN — 0 0 — NN
Mississippi — 0 0 — NN — 0 0 — NN
Tennessee§ — 0 0 — NN — 0 0 — NN
W.S. Central — 0 0 — NN — 0 0 — NN
Arkansas§ — 0 0 — NN — 0 0 — NN
Louisiana — 0 0 — NN — 0 0 — NN
Oklahoma — 0 0 — NN — 0 0 — NN
Texas§ — 0 0 — NN — 0 0 — NN
Mountain — 0 0 — NN — 0 0 — NN
Arizona — 0 0 — NN — 0 0 — NN
Colorado — 0 0 — NN — 0 0 — NN
Idaho§ — 0 0 — NN — 0 0 — NN
Montana§ — 0 0 — NN — 0 0 — NN
Nevada§ — 0 0 — NN — 0 0 — NN
New Mexico§ — 0 0 — NN — 0 0 — NN
Utah — 0 0 — NN — 0 0 — NN
Wyoming§ — 0 0 — NN — 0 0 — NN
Pacific — 0 0 — NN — 0 0 — NN
Alaska — 0 0 — NN — 0 0 — NN
California — 0 0 — NN — 0 0 — NN
Hawaii — 0 0 — NN — 0 0 — NN
Oregon — 0 0 — NN — 0 0 — NN
Washington — 0 0 — NN — 0 0 — NN
American Samoa — 0 0 — NN — 0 0 — NN
C.N.M.I. — — — — NN — — — — NN
Guam — 0 0 — NN — 0 0 — NN
Puerto Rico — 0 0 — NN — 0 0 — NN
U.S. Virgin Islands — 0 0 — NN — 0 0 — NN
C.N.M.I.: Commonwealth of Northern Mariana Islands.
U: Unavailable.   —: No reported cases.   N: Not reportable.   NN: Not Nationally Notifiable.   Cum: Cumulative year-to-date counts.   Med: Median.   Max: Maximum.
* Incidence data for reporting years 2009 and 2010 are provisional.
† DHF includes cases that meet criteria for dengue shock syndrome (DSS), a more severe form of DHF.
§ Contains data reported through the National Electronic Disease Surveillance System (NEDSS).
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TABLE II. (Continued) Provisional cases of selected notifiable diseases, United States, weeks ending May 22, 2010, and May 23, 2009 (20th week)*
Ehrlichiosis/Anaplasmosis†
Reporting area
Ehrlichia chaffeensis Anaplasma phagocytophilum Undetermined
Current 
week












Previous 52 weeks Cum 
2010
Cum 
2009Med Max Med Max Med Max
United States 9 10 153 52 99 6 13 302 19 96 — 2 37 5 39
New England — 0 4 2 4 — 2 21 5 23 — 0 1 — 1
Connecticut — 0 0 — — — 0 13 — — — 0 0 — —
Maine§ — 0 1 2 — — 0 3 2 3 — 0 0 — —
Massachusetts — 0 0 — — — 0 0 — — — 0 0 — —
New Hampshire — 0 1 — — — 0 3 1 6 — 0 1 — —
Rhode Island§ — 0 4 — 4 — 0 20 2 14 — 0 1 — 1
Vermont§ — 0 1 — — — 0 0 — — — 0 0 — —
Mid. Atlantic — 3 15 8 24 5 3 27 7 27 — 0 4 1 10
New Jersey — 1 8 — 14 — 0 7 — 11 — 0 0 — —
New York (Upstate) — 1 15 4 5 5 2 20 7 15 — 0 2 1 1
New York City — 0 2 3 1 — 0 1 — 1 — 0 1 — —
Pennsylvania — 0 5 1 4 — 0 1 — — — 0 3 — 9
E.N. Central — 0 8 — 19 — 2 23 1 43 — 1 7 1 15
Illinois — 0 4 — 8 — 0 1 — 1 — 0 1 — 1
Indiana — 0 0 — — — 0 0 — — — 0 6 1 10
Michigan — 0 0 — — — 0 0 — — — 0 0 — —
Ohio — 0 2 — 2 — 0 1 — 1 — 0 1 — —
Wisconsin — 0 3 — 9 — 2 22 1 41 — 0 4 — 4
W.N. Central 3 2 23 8 13 — 0 261 — — — 0 30 2 4
Iowa — 0 0 — — — 0 0 — — — 0 0 — —
Kansas — 0 2 — — — 0 1 — — — 0 0 — —
Minnesota — 0 6 — — — 0 261 — — — 0 30 — 2
Missouri 3 1 22 8 13 — 0 2 — — — 0 4 2 2
Nebraska§ — 0 1 — — — 0 1 — — — 0 0 — —
North Dakota — 0 0 — — — 0 0 — — — 0 0 — —
South Dakota — 0 0 — — — 0 0 — — — 0 0 — —
S. Atlantic 1 3 14 22 25 1 0 2 6 2 — 0 2 — —
Delaware — 0 2 3 3 — 0 1 1 — — 0 0 — —
District of Columbia — 0 0 — — — 0 0 — — — 0 0 — —
Florida — 0 1 2 2 — 0 1 — — — 0 0 — —
Georgia — 0 2 3 6 — 0 1 1 — — 0 0 — —
Maryland§ — 1 4 4 9 1 0 1 2 2 — 0 0 — —
North Carolina — 0 3 7 — — 0 1 1 — — 0 0 — —
South Carolina§ — 0 1 — 2 — 0 0 — — — 0 0 — —
Virginia§ 1 1 13 3 3 — 0 1 1 — — 0 2 — —
West Virginia — 0 1 — — — 0 0 — — — 0 1 — —
E.S. Central — 1 11 6 11 — 0 1 — 1 — 0 5 1 9
Alabama§ — 0 3 1 — — 0 1 — — — 0 0 — —
Kentucky — 0 2 — — — 0 0 — — — 0 0 — —
Mississippi — 0 2 — — — 0 0 — — — 0 0 — —
Tennessee§ — 1 10 5 11 — 0 1 — 1 — 0 5 1 9
W.S. Central 5 0 118 6 1 — 0 17 — — — 0 3 — —
Arkansas§ — 0 11 — — — 0 0 — — — 0 3 — —
Louisiana — 0 0 — — — 0 0 — — — 0 0 — —
Oklahoma 5 0 105 5 1 — 0 16 — — — 0 0 — —
Texas§ — 0 2 1 — — 0 1 — — — 0 0 — —
Mountain — 0 0 — — — 0 0 — — — 0 1 — —
Arizona — 0 0 — — — 0 0 — — — 0 1 — —
Colorado — 0 0 — — — 0 0 — — — 0 0 — —
Idaho§ — 0 0 — — — 0 0 — — — 0 0 — —
Montana§ — 0 0 — — — 0 0 — — — 0 0 — —
Nevada§ — 0 0 — — — 0 0 — — — 0 0 — —
New Mexico§ — 0 0 — — — 0 0 — — — 0 0 — —
Utah — 0 0 — — — 0 0 — — — 0 0 — —
Wyoming§ — 0 0 — — — 0 0 — — — 0 0 — —
Pacific — 0 1 — 2 — 0 1 — — — 0 1 — —
Alaska — 0 0 — — — 0 0 — — — 0 0 — —
California — 0 1 — 2 — 0 1 — — — 0 1 — —
Hawaii — 0 0 — — — 0 0 — — — 0 0 — —
Oregon — 0 0 — — — 0 0 — — — 0 0 — —
Washington — 0 0 — — — 0 0 — — — 0 0 — —
American Samoa — 0 0 — — — 0 0 — — — 0 0 — —
C.N.M.I. — — — — — — — — — — — — — — —
Guam — 0 0 — — — 0 0 — — — 0 0 — —
Puerto Rico — 0 0 — — — 0 0 — — — 0 0 — —
U.S. Virgin Islands — 0 0 — — — 0 0 — — — 0 0 — —
C.N.M.I.: Commonwealth of Northern Mariana Islands.
U: Unavailable.   —: No reported cases.   N: Not reportable.   NN: Not Nationally Notifiable.   Cum: Cumulative year-to-date counts.   Med: Median.   Max: Maximum.
* Incidence data for reporting years 2009 and 2010 are provisional.
† Cumulative total E. ewingii cases reported as of this week = 0.
§ Contains data reported through the National Electronic Disease Surveillance System (NEDSS).
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TABLE II. (Continued) Provisional cases of selected notifiable diseases, United States, weeks ending May 22, 2010, and May 23, 2009 (20th week)*
Reporting area
Giardiasis Gonorrhea
Haemophilus influenzae, invasive†  
All ages, all serotypes
Current 
week












Previous 52 weeks Cum 
2010
Cum 
2009Med Max Med Max Med Max
United States 193 339 660 5,626 6,072 2,305 5,502 6,929 83,382 116,217 19 55 171 1,078 1,252
New England 5 27 65 287 492 132 92 197 1,919 1,844 2 3 21 29 79
Connecticut — 6 15 94 95 34 45 170 893 849 1 0 15 12 23
Maine§ 3 4 13 72 71 4 3 11 80 58 — 0 2 3 12
Massachusetts — 10 36 — 211 77 39 81 767 750 — 0 8 — 38
New Hampshire — 3 11 44 42 7 2 7 61 41 — 0 2 7 3
Rhode Island§ — 1 7 19 23 10 6 19 108 123 — 0 2 4 1
Vermont§ 2 4 14 58 50 — 0 5 10 23 1 0 1 3 2
Mid. Atlantic 31 61 112 914 1,161 516 626 941 12,359 11,818 7 12 34 240 219
New Jersey — 6 15 1 169 87 90 132 1,713 1,807 — 2 7 31 35
New York (Upstate) 25 24 84 392 401 106 99 422 1,981 2,072 5 3 20 67 52
New York City — 16 25 271 330 215 215 396 4,511 4,205 — 2 6 47 29
Pennsylvania 6 15 37 250 261 108 206 277 4,154 3,734 2 4 9 95 103
E.N. Central 17 49 92 840 951 238 1,075 1,536 11,559 25,254 — 8 18 149 196
Illinois — 12 22 175 198 — 351 441 48 8,082 — 3 9 45 71
Indiana — 6 14 68 82 — 96 183 1,269 3,001 — 1 5 27 39
Michigan — 13 25 227 232 188 247 502 5,362 6,115 — 0 4 14 11
Ohio 17 16 28 321 297 50 311 359 4,307 5,935 — 2 6 50 43
Wisconsin — 7 23 49 142 — 91 115 573 2,121 — 1 5 13 32
W.N. Central 21 27 165 527 534 15 270 367 4,425 5,826 1 2 24 69 70
Iowa 6 6 15 95 96 4 31 46 592 660 — 0 1 1 —
Kansas 3 3 14 76 51 — 40 83 537 967 — 0 2 7 10
Minnesota — 0 135 136 137 — 42 64 702 912 1 0 17 22 15
Missouri 11 8 27 133 167 — 123 172 2,138 2,559 — 1 6 30 30
Nebraska§ 1 3 9 72 53 11 22 55 413 532 — 0 3 4 12
North Dakota — 0 8 9 4 — 2 11 43 44 — 0 4 5 3
South Dakota — 1 10 6 26 — 4 16 — 152 — 0 0 — —
S. Atlantic 64 73 144 1,402 1,327 574 1,328 1,774 17,551 28,988 6 14 27 276 355
Delaware — 0 3 10 12 17 19 37 386 313 — 0 1 3 3
District of Columbia — 1 4 10 24 — 43 86 616 1,090 — 0 1 — 1
Florida 45 37 87 688 695 176 381 482 7,210 8,330 2 3 10 84 117
Georgia 8 14 52 354 281 — 170 494 743 5,534 2 3 9 70 68
Maryland§ 3 5 12 114 100 — 126 237 2,027 2,280 1 1 6 19 43
North Carolina N 0 0 N N — 227 386 — 5,483 — 1 6 20 44
South Carolina§ 3 2 7 40 39 214 159 394 3,090 3,161 1 2 7 41 32
Virginia§ 5 9 37 173 160 163 163 271 3,295 2,567 — 2 5 31 32
West Virginia — 1 5 13 16 4 8 19 184 230 — 0 5 8 15
E.S. Central 1 7 22 94 135 276 472 649 8,198 10,137 1 3 12 71 82
Alabama§ — 4 13 51 63 129 135 187 2,787 2,850 — 0 2 7 22
Kentucky N 0 0 N N — 84 156 1,279 1,222 1 0 5 14 7
Mississippi N 0 0 N N — 127 198 1,637 2,908 — 0 2 6 9
Tennessee§ 1 4 18 43 72 147 144 206 2,495 3,157 — 2 10 44 44
W.S. Central 2 9 18 116 137 183 879 1,554 14,095 17,844 1 2 20 55 58
Arkansas§ — 2 9 32 43 98 87 139 1,652 1,735 — 0 3 7 10
Louisiana — 3 10 44 68 — 127 343 910 3,794 — 0 2 12 10
Oklahoma 2 3 10 40 26 85 69 616 1,543 985 — 1 15 31 35
Texas§ N 0 0 N N — 565 964 9,990 11,330 1 0 2 5 3
Mountain 8 31 64 529 474 53 168 266 2,591 3,405 — 5 14 144 121
Arizona 1 3 7 50 73 19 56 109 587 1,086 — 2 10 55 41
Colorado — 12 26 258 136 — 51 127 888 999 — 1 6 37 35
Idaho§ 1 4 10 78 44 4 1 8 28 38 — 0 2 6 2
Montana§ 3 3 11 47 37 — 2 6 44 36 — 0 1 1 1
Nevada§ 3 2 11 23 34 28 26 94 680 741 — 0 2 5 10
New Mexico§ — 1 8 25 41 — 19 41 238 359 — 1 5 22 17
Utah — 5 13 33 87 2 6 14 115 124 — 1 4 13 14
Wyoming§ — 1 5 15 22 — 1 7 11 22 — 0 2 5 1
Pacific 44 53 132 917 861 318 539 651 10,685 11,101 1 2 9 45 72
Alaska — 2 7 32 22 — 22 36 536 351 — 0 3 11 6
California 28 34 61 571 607 278 448 544 8,869 9,082 — 0 3 1 26
Hawaii — 0 2 — 7 — 10 24 207 254 — 0 2 — 15
Oregon 5 9 17 185 124 — 15 43 106 447 1 1 5 30 22
Washington 11 8 75 129 101 40 43 84 967 967 — 0 4 3 3
American Samoa — 0 0 — — — 0 0 — — — 0 0 — —
C.N.M.I. — — — — — — — — — — — — — — —
Guam — 0 1 1 — — 0 3 5 — — 0 0 — —
Puerto Rico — 1 10 9 57 — 4 24 97 82 — 0 1 1 1
U.S. Virgin Islands — 0 0 — — — 1 7 8 65 — 0 0 — —
C.N.M.I.: Commonwealth of Northern Mariana Islands.
U: Unavailable.   —: No reported cases.   N: Not reportable.   NN: Not Nationally Notifiable.   Cum: Cumulative year-to-date counts.   Med: Median.   Max: Maximum.
* Incidence data for reporting years 2009 and 2010 are provisional.
† Data for H. influenzae (age <5 yrs for serotype b, nonserotype b, and unknown serotype) are available in Table I.
§ Contains data reported through the National Electronic Disease Surveillance System (NEDSS).
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TABLE II. (Continued) Provisional cases of selected notifiable diseases, United States, weeks ending May 22, 2010, and May 23, 2009 (20th week)*

















Previous 52 weeks Cum 
2010
Cum 
2009Med Max Med Max Med Max
United States 22 33 67 501 745 25 57 202 967 1,334 9 15 43 270 294
New England 1 1 5 19 41 — 1 4 19 25 — 1 5 9 21
Connecticut 1 0 2 12 9 — 0 3 5 5 — 1 4 9 17
Maine† — 0 1 3 1 — 0 2 8 5 — 0 1 — —
Massachusetts — 1 4 — 23 — 0 2 — 12 — 0 1 — 3
New Hampshire — 0 1 — 4 — 0 2 5 3 — 0 0 — —
Rhode Island† — 0 4 4 3 — 0 0 — — — 0 0 — —
Vermont† — 0 1 — 1 — 0 1 1 — — 0 0 — 1
Mid. Atlantic 3 4 10 71 93 1 5 10 105 157 1 2 4 32 37
New Jersey — 1 5 8 29 — 1 4 21 54 — 0 2 2 5
New York (Upstate) 3 1 3 21 16 1 1 6 20 26 1 1 3 20 17
New York City — 2 5 23 22 — 1 4 31 28 — 0 1 — 1
Pennsylvania — 1 6 19 26 — 1 5 33 49 — 0 4 10 14
E.N. Central 2 4 19 61 118 2 7 14 130 194 — 2 5 47 38
Illinois — 1 13 13 44 — 2 6 23 44 — 0 1 — 3
Indiana — 0 4 5 9 — 1 5 18 36 — 0 3 8 5
Michigan — 1 4 24 30 — 2 6 44 54 — 1 4 37 12
Ohio 2 0 4 14 22 2 2 4 45 51 — 0 3 2 16
Wisconsin — 0 2 5 13 — 0 3 — 9 — 0 1 — 2
W.N. Central — 1 10 21 46 1 3 15 51 48 1 0 11 14 4
Iowa — 0 3 4 14 — 1 3 8 10 — 0 4 2 2
Kansas — 0 2 6 4 — 0 2 2 4 — 0 0 — 1
Minnesota — 0 8 1 11 — 0 13 2 10 — 0 9 3 —
Missouri — 0 3 9 8 1 1 5 31 15 1 0 1 7 —
Nebraska† — 0 3 1 8 — 0 2 8 8 — 0 1 1 1
North Dakota — 0 1 — — — 0 0 — — — 0 1 — —
South Dakota — 0 1 — 1 — 0 1 — 1 — 0 1 1 —
S. Atlantic 4 7 14 117 174 10 16 39 293 363 4 3 8 59 83
Delaware — 0 1 5 2 U 1 2 U U U 0 0 U U
District of Columbia — 0 1 — — — 0 2 — 4 — 0 1 — —
Florida 3 3 8 44 83 5 5 11 117 124 3 1 4 22 10
Georgia — 1 3 16 13 2 3 7 58 55 — 0 2 4 19
Maryland† — 0 4 9 18 1 1 6 23 42 1 1 3 12 17
North Carolina — 0 3 11 31 — 1 4 4 53 — 0 4 9 17
South Carolina† — 1 4 18 15 — 1 4 15 16 — 0 0 — 1
Virginia† 1 1 3 13 12 2 2 14 40 34 — 0 2 6 6
West Virginia — 0 2 1 — — 0 19 25 21 — 0 3 6 13
E.S. Central — 1 3 16 20 2 7 13 103 156 2 2 6 49 42
Alabama† — 0 2 4 3 — 1 5 23 45 — 0 2 1 5
Kentucky — 0 2 9 1 1 2 6 34 34 1 1 5 36 23
Mississippi — 0 2 — 11 — 0 5 8 20 — 0 0 — —
Tennessee† — 0 2 3 5 1 2 6 38 57 1 0 3 12 14
W.S. Central 3 3 19 52 67 5 10 109 131 208 — 1 14 20 18
Arkansas† — 0 3 — 4 — 0 4 3 21 — 0 1 — 1
Louisiana — 0 1 3 1 — 1 5 16 23 — 0 1 2 4
Oklahoma — 0 3 — 1 4 1 19 25 43 — 0 12 9 2
Texas† 3 2 18 49 61 1 6 87 87 121 — 0 4 9 11
Mountain 1 3 8 56 52 2 2 6 34 54 — 1 4 16 21
Arizona — 1 5 31 18 — 0 3 11 23 — 0 0 — —
Colorado — 1 4 9 16 — 0 2 1 11 — 0 3 2 12
Idaho† 1 0 1 3 — 1 0 2 4 2 — 0 2 6 1
Montana† — 0 1 3 3 — 0 1 — — — 0 1 — 1
Nevada† — 0 2 6 7 1 1 3 14 8 — 0 1 1 1
New Mexico† — 0 1 3 5 — 0 1 2 4 — 0 2 5 4
Utah — 0 2 1 3 — 0 1 2 4 — 0 1 2 2
Wyoming† — 0 1 — — — 0 1 — 2 — 0 0 — —
Pacific 8 5 16 88 134 2 6 20 101 129 1 1 6 24 30
Alaska — 0 0 — 3 — 0 1 1 2 — 0 2 — —
California 7 4 15 73 100 — 4 16 72 93 1 1 4 8 14
Hawaii — 0 2 — 6 — 0 1 — 3 — 0 0 — —
Oregon — 0 2 8 6 — 1 4 15 16 — 0 3 9 8
Washington 1 0 4 7 19 2 0 4 13 15 — 0 6 7 8
American Samoa — 0 0 — — — 0 0 — — — 0 0 — —
C.N.M.I. — — — — — — — — — — — — — — —
Guam — 0 6 10 — — 1 6 22 — — 1 5 19 —
Puerto Rico — 0 2 2 13 — 0 5 7 11 — 0 0 — —
U.S. Virgin Islands — 0 0 — — — 0 0 — — — 0 0 — —
C.N.M.I.: Commonwealth of Northern Mariana Islands.
U: Unavailable.   —: No reported cases.   N: Not reportable.   NN: Not Nationally Notifiable.   Cum: Cumulative year-to-date counts.   Med: Median.   Max: Maximum.
* Incidence data for reporting years 2009 and 2010 are provisional.
† Contains data reported through the National Electronic Disease Surveillance System (NEDSS).
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TABLE II. (Continued) Provisional cases of selected notifiable diseases, United States, weeks ending May 22, 2010, and May 23, 2009 (20th week)*
Reporting area
Legionellosis Lyme disease Malaria
Current 
week












Previous 52 weeks Cum 
2010
Cum 
2009Med Max Med Max Med Max
United States 29 58 174 614 641 138 431 2,336 3,561 5,264 13 26 87 358 413
New England 1 3 18 20 25 32 118 853 624 1,899 — 1 4 4 16
Connecticut 1 1 5 10 6 2 34 295 232 817 — 0 3 — 1
Maine† — 0 3 2 — 29 13 76 142 63 — 0 1 1 —
Massachusetts — 1 9 — 17 — 35 397 — 701 — 0 3 — 11
New Hampshire — 0 3 2 — — 18 95 206 262 — 0 1 1 1
Rhode Island† — 0 4 5 1 — 1 29 10 15 — 0 1 1 2
Vermont† — 0 1 1 1 1 5 45 34 41 — 0 1 1 1
Mid. Atlantic 6 18 73 139 167 76 199 999 1,999 1,994 3 7 17 96 116
New Jersey — 3 14 — 32 — 39 429 437 790 — 1 5 — 31
New York (Upstate) 1 5 29 45 55 55 53 577 459 515 3 1 4 26 17
New York City — 3 19 30 20 — 13 58 2 174 — 3 12 49 53
Pennsylvania 5 6 25 64 60 21 66 475 1,101 515 — 1 4 21 15
E.N. Central 4 11 41 105 133 — 21 258 64 322 2 2 12 36 52
Illinois — 1 11 7 19 — 1 12 5 16 — 1 6 17 23
Indiana — 1 5 8 16 — 1 6 9 12 — 0 4 2 8
Michigan — 3 13 27 20 — 1 9 4 4 — 0 3 4 6
Ohio 4 5 17 61 59 — 1 5 5 4 2 0 6 13 13
Wisconsin — 0 6 2 19 — 18 239 41 286 — 0 2 — 2
W.N. Central 1 2 19 24 22 — 4 1,395 11 49 — 1 11 21 19
Iowa — 0 3 2 8 — 0 15 4 13 — 0 1 6 4
Kansas — 0 1 2 3 — 0 2 3 7 — 0 1 3 1
Minnesota — 0 16 9 — — 0 1,380 — 26 — 0 11 3 9
Missouri 1 1 5 7 6 — 0 1 1 1 — 0 1 3 3
Nebraska† — 0 2 2 4 — 0 3 3 1 — 0 2 6 1
North Dakota — 0 1 2 1 — 0 15 — — — 0 1 — —
South Dakota — 0 1 — — — 0 0 — 1 — 0 0 — 1
S. Atlantic 6 11 24 136 136 28 68 255 744 912 5 6 15 101 130
Delaware — 0 5 5 1 2 12 65 193 206 — 0 1 2 1
District of Columbia — 0 5 2 5 — 0 7 3 9 — 0 3 5 5
Florida 3 4 10 60 53 1 2 11 26 11 2 2 7 45 34
Georgia — 1 4 17 19 — 0 6 3 10 — 0 6 2 24
Maryland† 3 3 12 30 25 19 27 134 334 475 1 1 13 21 35
North Carolina — 0 5 2 19 — 1 7 12 31 — 0 3 5 14
South Carolina† — 0 2 1 2 — 1 3 10 11 — 0 1 1 1
Virginia† — 1 6 17 12 6 13 79 149 126 2 1 5 20 15
West Virginia — 0 2 2 — — 0 33 14 33 — 0 2 — 1
E.S. Central 4 2 12 27 33 — 1 4 12 7 — 0 4 6 14
Alabama† — 0 2 3 6 — 0 1 — 1 — 0 3 1 3
Kentucky — 1 3 8 13 — 0 1 1 1 — 0 3 2 4
Mississippi — 0 4 2 1 — 0 0 — — — 0 2 — —
Tennessee† 4 1 9 14 13 — 1 4 11 5 — 0 1 3 7
W.S. Central 3 2 14 27 34 — 4 44 18 24 1 1 31 41 11
Arkansas† — 0 1 1 3 — 0 0 — — — 0 1 1 —
Louisiana — 0 3 1 3 — 0 0 — — — 0 1 — 3
Oklahoma 3 0 4 3 1 — 0 2 — — 1 0 1 3 —
Texas† — 1 10 22 27 — 4 42 18 24 — 1 30 37 8
Mountain 1 3 8 37 37 — 1 4 5 12 — 1 6 13 11
Arizona — 1 4 14 14 — 0 1 — 1 — 0 2 6 1
Colorado — 0 4 2 4 — 0 1 1 — — 0 3 1 8
Idaho† — 0 2 — 1 — 0 3 2 3 — 0 1 — —
Montana† — 0 1 1 4 — 0 1 — 1 — 0 3 1 —
Nevada† 1 0 2 11 6 — 0 2 — 4 — 0 1 2 —
New Mexico† — 0 2 2 1 — 0 1 1 — — 0 0 — —
Utah — 0 4 6 6 — 0 1 1 3 — 0 1 3 2
Wyoming† — 0 2 1 1 — 0 1 — — — 0 0 — —
Pacific 3 4 19 99 54 2 4 10 84 45 2 2 19 40 44
Alaska — 0 0 — 1 — 0 1 1 2 — 0 1 2 1
California 3 3 19 91 46 2 3 9 56 27 1 2 13 28 32
Hawaii — 0 0 — 1 N 0 0 N N — 0 0 — 1
Oregon — 0 3 1 3 — 1 4 26 14 — 0 1 3 6
Washington — 0 4 7 3 — 0 3 1 2 1 0 5 7 4
American Samoa — 0 0 — — N 0 0 N N — 0 0 — —
C.N.M.I. — — — — — — — — — — — — — — —
Guam — 0 0 — — — 0 0 — — — 0 0 — —
Puerto Rico — 0 1 — — N 0 0 N N — 0 2 1 1
U.S. Virgin Islands — 0 0 — — — 0 0 — — — 0 0 — —
C.N.M.I.: Commonwealth of Northern Mariana Islands.
U: Unavailable.   —: No reported cases.   N: Not reportable.   NN: Not Nationally Notifiable.   Cum: Cumulative year-to-date counts.   Med: Median.   Max: Maximum.
* Incidence data for reporting years 2009 and 2010 are provisional.
† Contains data reported through the National Electronic Disease Surveillance System (NEDSS).
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TABLE II. (Continued) Provisional cases of selected notifiable diseases, United States, weeks ending May 22, 2010, and May 23, 2009 (20th week)*
Reporting area
Meningococcal disease, invasive† 
All groups Pertussis Rabies, animal
Current 
week












Previous 52 weeks Cum 
2010
Cum 
2009Med Max Med Max Med Max
United States 5 16 43 310 457 93 270 1,748 3,488 5,080 25 77 147 926 1,952
New England — 0 2 4 16 — 7 23 29 250 3 5 24 92 121
Connecticut — 0 2 — 2 — 1 4 14 14 — 1 22 43 49
Maine§ — 0 1 1 2 — 0 10 5 35 2 1 4 24 20
Massachusetts — 0 1 — 9 — 4 12 — 161 — 0 0 — —
New Hampshire — 0 1 — 1 — 1 6 3 26 — 0 3 3 13
Rhode Island§ — 0 1 — 1 — 0 8 4 8 — 0 5 3 13
Vermont§ — 0 1 3 1 — 0 1 3 6 1 1 5 19 26
Mid. Atlantic — 2 4 30 50 4 20 42 232 441 11 10 23 231 231
New Jersey — 0 2 8 6 — 3 10 29 97 — 0 0 — —
New York (Upstate) — 0 3 6 11 2 5 27 94 68 11 9 22 171 129
New York City — 0 2 7 10 — 0 11 3 35 — 0 11 60 2
Pennsylvania — 0 2 9 23 2 9 22 106 241 — 0 0 — 100
E.N. Central — 2 7 44 78 34 56 105 882 1,014 5 2 19 33 43
Illinois — 0 4 7 20 — 9 29 122 253 1 1 9 15 16
Indiana — 0 2 11 19 — 6 16 60 122 — 0 7 — 11
Michigan — 0 5 7 12 4 17 41 280 215 3 1 6 12 14
Ohio — 1 2 16 19 30 19 49 415 369 1 0 5 6 2
Wisconsin — 0 1 3 8 — 2 12 5 55 — 0 0 — —
W.N. Central 1 1 6 20 35 6 26 627 262 886 4 6 18 78 138
Iowa — 0 2 3 4 — 4 12 71 77 — 0 4 — 9
Kansas — 0 2 1 6 — 3 12 45 85 — 1 4 22 40
Minnesota — 0 2 2 8 — 0 601 6 168 — 0 9 13 18
Missouri 1 0 3 9 12 1 12 35 104 463 3 1 5 18 14
Nebraska§ — 0 2 5 3 5 2 5 33 82 1 1 6 22 36
North Dakota — 0 1 — — — 0 12 — 2 — 0 7 3 4
South Dakota — 0 2 — 2 — 0 6 3 9 — 0 4 — 17
S. Atlantic 1 2 7 65 92 12 22 63 331 547 1 31 58 368 903
Delaware — 0 1 1 2 — 0 2 — 6 — 0 0 — —
District of Columbia — 0 0 — — — 0 1 2 3 — 0 0 — —
Florida 1 1 5 35 28 6 6 29 84 182 — 0 21 38 161
Georgia — 0 2 6 16 4 3 8 71 106 — 5 14 — 173
Maryland§ — 0 1 2 4 2 3 8 43 46 — 7 15 130 137
North Carolina — 0 2 5 24 — 1 9 — 83 — 6 17 — 187
South Carolina§ — 0 1 5 6 — 4 18 82 55 — 0 0 — —
Virginia§ — 0 2 10 8 — 4 15 42 61 — 10 26 171 206
West Virginia — 0 2 1 4 — 0 6 7 5 1 2 6 29 39
E.S. Central 1 0 4 17 19 4 15 31 276 312 1 1 7 46 60
Alabama§ — 0 2 4 4 — 5 17 66 97 — 0 4 14 —
Kentucky 1 0 2 6 3 2 4 15 112 92 1 0 2 3 24
Mississippi — 0 2 2 4 — 2 12 18 55 — 0 2 — 2
Tennessee§ — 0 2 5 8 2 4 10 80 68 — 0 6 29 34
W.S. Central 1 1 9 37 37 23 70 754 987 854 — 10 40 10 327
Arkansas§ — 0 2 3 5 — 5 30 30 99 — 0 10 6 11
Louisiana — 0 3 8 9 1 1 10 9 75 — 0 0 — —
Oklahoma — 0 7 12 2 — 0 41 5 11 — 0 15 4 4
Texas§ 1 1 7 14 21 22 61 681 943 669 — 9 30 — 312
Mountain — 1 4 24 39 6 17 41 294 408 — 2 8 15 42
Arizona — 0 2 7 7 1 6 12 110 73 — 0 5 — —
Colorado — 0 3 6 11 — 3 13 42 106 — 0 0 — —
Idaho§ — 0 1 3 5 5 1 19 60 39 — 0 2 1 —
Montana§ — 0 2 1 5 — 1 6 7 10 — 0 4 — 13
Nevada§ — 0 1 4 3 — 0 6 2 6 — 0 1 — —
New Mexico§ — 0 1 2 3 — 1 6 29 30 — 0 3 4 15
Utah — 0 1 1 1 — 3 6 43 127 — 0 2 — 1
Wyoming§ — 0 1 — 4 — 0 3 1 17 — 0 3 10 13
Pacific 1 3 16 69 91 4 25 186 195 368 — 4 12 53 87
Alaska — 0 2 — 3 — 0 4 11 26 — 0 2 11 16
California — 2 13 48 57 — 11 162 27 137 — 3 11 38 71
Hawaii — 0 2 — 3 — 0 4 — 13 — 0 0 — —
Oregon — 0 5 12 19 2 5 12 104 86 — 0 2 4 —
Washington 1 0 7 9 9 2 5 24 53 106 — 0 0 — —
American Samoa — 0 0 — — — 0 0 — — N 0 0 N N
C.N.M.I. — — — — — — — — — — — — — — —
Guam — 0 0 — — — 0 0 — — — 0 0 — —
Puerto Rico — 0 1 — — — 0 0 — 1 — 1 3 19 20
U.S. Virgin Islands — 0 0 — — — 0 0 — — — 0 0 — —
C.N.M.I.: Commonwealth of Northern Mariana Islands.
U: Unavailable.   —: No reported cases.   N: Not reportable.   NN: Not Nationally Notifiable.   Cum: Cumulative year-to-date counts.   Med: Median.   Max: Maximum.
* Incidence data for reporting years 2009 and 2010 are provisional.
† Data for meningococcal disease, invasive caused by serogroups A, C, Y, and W-135; serogroup B; other serogroup; and unknown serogroup are available in Table I.
§ Contains data reported through the National Electronic Disease Surveillance System (NEDSS).
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TABLE II. (Continued) Provisional cases of selected notifiable diseases, United States, weeks ending May 22, 2010, and May 23, 2009 (20th week)*
Reporting area
Salmonellosis Shiga toxin-producing E. coli (STEC)† Shigellosis
Current 
week












Previous 52 weeks Cum 
2010
Cum 
2009Med Max Med Max Med Max
United States 422 973 1,525 9,617 13,205 38 83 194 821 1,220 207 278 523 4,329 6,046
New England 3 24 140 260 1,067 — 2 30 28 120 — 3 28 26 111
Connecticut — 0 135 135 430 — 0 14 14 67 — 0 15 15 43
Maine§ 2 2 7 27 40 — 0 3 3 8 — 0 2 3 2
Massachusetts — 16 47 — 379 — 1 6 — 28 — 2 27 — 54
New Hampshire — 3 9 48 149 — 1 3 9 12 — 0 5 3 2
Rhode Island§ — 2 11 33 49 — 0 26 — — — 0 7 4 7
Vermont§ 1 1 5 17 20 — 0 3 2 5 — 0 1 1 3
Mid. Atlantic 43 84 208 1,268 1,519 5 7 23 98 131 13 39 90 580 1,181
New Jersey — 18 47 162 315 — 1 5 5 41 1 6 23 90 304
New York (Upstate) 24 24 78 345 345 5 3 15 45 33 7 4 19 66 63
New York City — 22 46 308 346 — 1 4 9 25 — 7 15 96 189
Pennsylvania 19 29 67 453 513 — 2 8 39 32 5 23 63 328 625
E.N. Central 49 76 167 1,028 1,695 6 10 30 99 220 18 29 233 695 1,219
Illinois — 25 52 338 493 — 2 6 10 73 — 9 227 501 290
Indiana — 10 30 36 162 — 1 10 9 26 — 1 5 7 32
Michigan 2 15 34 211 355 2 2 7 38 35 — 4 10 66 109
Ohio 47 24 52 409 462 4 2 11 36 36 18 9 46 109 597
Wisconsin — 11 30 34 223 — 2 11 6 50 — 4 23 12 191
W.N. Central 22 45 94 646 895 5 10 39 147 144 65 42 88 1,045 274
Iowa 1 7 16 95 140 — 2 14 22 34 — 0 5 18 38
Kansas 3 7 20 99 110 1 1 5 12 18 4 4 14 84 84
Minnesota — 10 32 177 206 — 2 17 31 31 — 1 6 14 26
Missouri 13 13 29 203 161 2 2 27 66 35 61 35 75 919 113
Nebraska§ 5 4 12 57 169 2 1 6 15 23 — 0 3 10 10
North Dakota — 0 39 8 12 — 0 7 — 1 — 0 5 — 1
South Dakota — 1 9 7 97 — 0 12 1 2 — 0 1 — 2
S. Atlantic 133 286 503 2,719 2,942 10 12 22 156 217 46 40 73 634 888
Delaware — 2 9 27 23 — 0 2 1 5 — 3 10 31 26
District of Columbia — 2 6 23 37 — 0 1 2 1 — 0 3 11 12
Florida 69 132 277 1,317 1,249 3 3 7 60 63 19 11 18 240 167
Georgia 30 42 105 422 499 1 1 4 18 21 18 12 23 229 235
Maryland§ 12 15 32 229 240 3 1 6 21 27 1 4 17 35 146
North Carolina — 34 90 230 374 — 1 5 4 47 — 2 26 15 166
South Carolina§ 6 16 66 179 210 — 0 3 5 10 2 1 6 28 61
Virginia§ 11 19 68 229 260 3 3 13 42 36 6 3 15 44 70
West Virginia 5 4 23 63 50 — 0 5 3 7 — 0 2 1 5
E.S. Central 15 58 153 527 924 1 4 10 46 72 5 13 43 189 382
Alabama§ 1 14 40 151 237 — 1 4 11 11 — 2 10 22 74
Kentucky 7 7 18 111 149 — 1 4 5 21 4 3 22 83 94
Mississippi — 25 87 98 342 1 0 1 7 12 — 1 8 11 24
Tennessee§ 7 14 33 167 196 — 1 8 23 28 1 5 15 73 190
W.S. Central 42 110 546 898 1,297 1 5 68 38 80 37 47 250 690 1,150
Arkansas§ — 9 25 54 146 — 0 4 5 8 — 4 15 12 121
Louisiana 2 21 46 206 266 — 0 3 4 11 1 3 7 60 88
Oklahoma 13 10 46 117 166 1 0 27 2 6 12 6 96 123 73
Texas§ 27 59 477 521 719 — 3 41 27 55 24 35 144 495 868
Mountain 10 50 133 711 954 3 7 26 94 130 1 15 48 178 411
Arizona 1 18 50 238 333 — 1 4 21 15 1 11 42 93 281
Colorado — 11 33 193 193 — 2 11 16 60 — 2 6 28 33
Idaho§ 3 3 10 44 58 1 1 7 13 12 — 0 1 5 2
Montana§ 1 2 7 34 47 — 0 7 15 6 — 0 1 4 11
Nevada§ 4 4 13 65 96 2 0 4 9 7 — 1 7 11 28
New Mexico§ — 5 40 73 92 — 1 3 10 13 — 1 9 33 46
Utah — 5 14 49 111 — 1 11 9 16 — 0 4 4 10
Wyoming§ 1 1 9 15 24 — 0 2 1 1 — 0 2 — —
Pacific 105 122 299 1,560 1,912 7 9 46 115 106 22 21 64 292 430
Alaska — 1 7 29 21 — 0 0 — — — 0 2 — 1
California 63 92 227 1,116 1,457 2 5 35 60 69 20 16 51 246 335
Hawaii — 4 62 — 86 — 0 2 — 3 — 0 4 — 9
Oregon 4 9 45 224 143 — 1 11 11 9 — 1 5 22 22
Washington 38 14 61 191 205 5 3 19 44 25 2 2 9 24 63
American Samoa — 1 1 1 — — 0 0 — — — 1 1 1 3
C.N.M.I. — — — — — — — — — — — — — — —
Guam — 0 1 1 — — 0 0 — — — 0 0 — —
Puerto Rico — 8 39 67 194 — 0 0 — — — 0 1 — 5
U.S. Virgin Islands — 0 0 — — — 0 0 — — — 0 0 — —
C.N.M.I.: Commonwealth of Northern Mariana Islands.
U: Unavailable.   —: No reported cases.   N: Not reportable.   NN: Not Nationally Notifiable.   Cum: Cumulative year-to-date counts.   Med: Median.   Max: Maximum.
* Incidence data for reporting years 2009 and 2010 are provisional.
† Includes E. coli O157:H7; Shiga toxin-positive, serogroup non-O157; and Shiga toxin-positive, not serogrouped.
§ Contains data reported through the National Electronic Disease Surveillance System (NEDSS).
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TABLE II. (Continued) Provisional cases of selected notifiable diseases, United States, weeks ending May 22, 2010, and May 23, 2009 (20th week)*











Previous 52 weeks Cum  
2010
Cum  
2009Med Max Med Max
United States — 2 12 16 31 15 11 354 135 305
New England — 0 1 — — — 0 1 1 4
Connecticut — 0 0 — — — 0 0 — —
Maine§ — 0 0 — — — 0 1 1 3
Massachusetts — 0 1 — — — 0 1 — 1
New Hampshire — 0 0 — — — 0 1 — —
Rhode Island§ — 0 0 — — — 0 0 — —
Vermont§ — 0 1 — — — 0 0 — —
Mid. Atlantic — 0 2 3 — — 1 7 11 24
New Jersey — 0 1 — — — 0 4 — 18
New York (Upstate) — 0 1 — — — 0 3 2 1
New York City — 0 1 — — — 0 2 7 2
Pennsylvania — 0 2 3 — — 0 2 2 3
E.N. Central — 0 1 — 3 — 0 7 — 22
Illinois — 0 1 — — — 0 6 — 12
Indiana — 0 1 — 2 — 0 2 — 1
Michigan — 0 1 — 1 — 0 1 — —
Ohio — 0 0 — — — 0 4 — 8
Wisconsin — 0 1 — — — 0 1 — 1
W.N. Central — 0 3 1 3 4 2 23 33 41
Iowa — 0 1 — — — 0 1 — 2
Kansas — 0 1 — — — 0 0 — —
Minnesota — 0 1 — — — 0 1 — —
Missouri — 0 1 1 1 4 2 22 33 39
Nebraska§ — 0 2 — 2 — 0 1 — —
North Dakota — 0 0 — — — 0 0 — —
South Dakota — 0 0 — — — 0 0 — —
S. Atlantic — 1 7 9 20 3 3 31 50 125
Delaware — 0 1 1 — — 0 3 5 3
District of Columbia — 0 0 — — — 0 1 — —
Florida — 0 1 1 — 1 0 1 3 1
Georgia — 0 6 5 18 — 0 0 — —
Maryland§ — 0 1 1 — — 0 3 3 18
North Carolina — 0 2 1 1 — 2 23 27 74
South Carolina§ — 0 1 — 1 — 0 1 2 12
Virginia§ — 0 1 — — 2 0 5 10 17
West Virginia — 0 0 — — — 0 1 — —
E.S. Central — 0 2 2 1 1 3 16 27 65
Alabama§ — 0 1 — — — 1 7 5 10
Kentucky — 0 1 1 — — 0 0 — —
Mississippi — 0 0 — 1 — 0 4 — 4
Tennessee§ — 0 2 1 — 1 2 13 22 51
W.S. Central — 0 3 1 — 6 1 346 12 17
Arkansas§ — 0 0 — — — 0 48 — 2
Louisiana — 0 0 — — — 0 1 — 1
Oklahoma — 0 3 — — 6 0 287 8 3
Texas§ — 0 1 1 — — 0 11 4 11
Mountain — 0 2 — 3 1 0 3 1 7
Arizona — 0 2 — 1 — 0 2 — 2
Colorado — 0 1 — — — 0 0 — —
Idaho§ — 0 0 — — 1 0 1 1 —
Montana§ — 0 1 — 2 — 0 1 — 3
Nevada§ — 0 0 — — — 0 1 — —
New Mexico§ — 0 0 — — — 0 0 — 1
Utah — 0 0 — — — 0 0 — 1
Wyoming§ — 0 1 — — — 0 1 — —
Pacific — 0 0 — 1 — 0 0 — —
Alaska N 0 0 N N N 0 0 N N
California — 0 0 — 1 — 0 0 — —
Hawaii N 0 0 N N N 0 0 N N
Oregon — 0 0 — — — 0 0 — —
Washington — 0 0 — — — 0 0 — —
American Samoa N 0 0 N N N 0 0 N N
C.N.M.I. — — — — — — — — — —
Guam N 0 0 N N N 0 0 N N
Puerto Rico N 0 0 N N N 0 0 N N
U.S. Virgin Islands — 0 0 — — — 0 0 — —
C.N.M.I.: Commonwealth of Northern Mariana Islands.
U: Unavailable.   —: No reported cases.   N: Not reportable.   NN: Not Nationally Notifiable.   Cum: Cumulative year-to-date counts.   Med: Median.   Max: Maximum.
* Incidence data for reporting years 2009 and 2010 are provisional.
† Illnesses with similar clinical presentation that result from Spotted fever group rickettsia infections are reported as Spotted fever rickettsioses. Rocky Mountain spotted fever (RMSF) caused 
by Rickettsia rickettsii, is the most common and well-known spotted fever.
§ Contains data reported through the National Electronic Disease Surveillance System (NEDSS).
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TABLE II. (Continued) Provisional cases of selected notifiable diseases, United States, weeks ending May 22, 2010, and May 23, 2009 (20th week)*
Streptococcus pneumoniae,† invasive disease
Reporting area
All ages Age <5 Syphilis, primary and secondary
Current 
week












Previous 52 weeks Cum 
2010
Cum 
2009Med Max Med Max Med Max
United States 151 60 427 6,522 1,638 20 48 160 1,054 1,179 64 237 414 3,735 5,356
New England 7 2 97 387 28 — 1 23 34 39 9 7 22 165 130
Connecticut 2 0 94 194 — — 0 22 22 — 3 1 10 35 27
Maine§ 3 1 6 58 7 — 0 2 6 — — 0 3 14 1
Massachusetts — 0 1 — 2 — 0 5 — 31 5 4 12 97 88
New Hampshire — 0 7 56 — — 0 2 3 5 — 0 1 5 10
Rhode Island§ — 0 7 40 11 — 0 1 2 1 1 0 5 12 4
Vermont§ 2 0 6 39 8 — 0 1 1 2 — 0 2 2 —
Mid. Atlantic 12 6 44 464 96 4 6 52 137 138 24 33 47 640 714
New Jersey — 0 5 45 — — 1 4 25 24 3 4 12 87 98
New York (Upstate) 4 2 12 88 39 3 3 19 63 67 3 2 11 38 43
New York City 1 1 19 98 3 1 1 28 23 38 13 18 39 381 437
Pennsylvania 7 2 21 233 54 — 0 5 26 9 5 6 14 134 136
E.N. Central 17 13 75 904 375 4 8 18 161 193 1 25 43 251 556
Illinois — 0 7 43 — — 1 5 37 32 — 13 20 7 265
Indiana — 5 20 227 153 — 1 6 26 37 — 2 9 38 67
Michigan 8 1 26 328 17 1 1 6 40 35 — 3 13 84 89
Ohio 9 8 19 215 205 3 2 6 49 68 1 7 13 122 118
Wisconsin — 0 20 91 — — 0 2 9 21 — 0 2 — 17
W.N. Central 17 4 182 469 99 2 3 12 87 88 — 5 12 74 122
Iowa — 0 0 — — — 0 0 — — — 0 2 2 10
Kansas 1 1 7 55 40 1 0 2 11 13 — 0 3 4 8
Minnesota 12 0 179 269 18 — 1 10 41 29 — 1 4 15 33
Missouri 1 1 8 62 33 — 1 3 25 31 — 3 8 49 64
Nebraska§ 3 0 7 63 — 1 0 2 9 4 — 0 2 4 5
North Dakota — 0 10 16 6 — 0 1 — 4 — 0 1 — 2
South Dakota — 0 2 4 2 — 0 1 1 7 — 0 0 — —
S. Atlantic 47 29 142 1,726 735 5 12 28 280 294 9 60 218 971 1,218
Delaware 1 0 3 18 10 — 0 2 — — — 0 3 3 14
District of Columbia 1 0 4 17 11 1 0 1 6 2 — 2 8 41 70
Florida 27 16 89 833 440 2 3 18 104 110 1 19 32 339 447
Georgia 5 8 28 271 206 2 4 12 78 69 1 13 167 156 219
Maryland§ 8 0 25 237 4 — 1 6 30 46 — 6 12 95 108
North Carolina — 0 0 — — — 0 0 — — — 11 31 171 195
South Carolina§ 5 0 25 270 — — 1 4 28 27 3 2 6 51 48
Virginia§ — 0 4 26 — — 1 4 24 27 4 4 22 113 113
West Virginia — 1 21 54 64 — 0 4 10 13 — 0 2 2 4
E.S. Central 16 5 50 617 173 1 3 9 59 77 6 19 40 298 462
Alabama§ — 0 0 — — — 0 0 — — 4 6 18 100 184
Kentucky 5 1 15 84 48 — 0 2 6 7 — 1 13 29 23
Mississippi — 1 6 32 28 — 0 4 6 15 — 4 17 54 77
Tennessee§ 11 2 44 501 97 1 2 7 47 55 2 7 15 115 178
W.S. Central 20 4 89 870 62 2 6 41 143 167 6 45 75 568 1,103
Arkansas§ — 1 8 63 30 — 0 4 9 23 6 6 16 97 74
Louisiana — 1 8 43 32 — 0 3 16 16 — 8 27 64 345
Oklahoma 1 0 5 30 — 1 1 5 30 27 — 1 6 20 38
Texas§ 19 0 81 734 — 1 4 34 88 101 — 28 46 387 646
Mountain 9 3 82 947 68 1 5 12 134 165 5 8 18 109 203
Arizona 7 0 51 464 — — 2 7 59 75 1 3 10 21 100
Colorado — 0 20 270 — — 1 4 36 25 — 2 5 41 37
Idaho§ 1 0 1 8 — 1 0 1 4 4 — 0 1 2 2
Montana§ — 0 1 8 — — 0 0 — — — 0 1 — —
Nevada§ 1 1 4 36 27 — 0 1 4 6 4 1 10 34 36
New Mexico§ — 0 8 79 — — 0 4 12 19 — 1 4 7 19
Utah — 1 9 74 34 — 1 4 17 35 — 0 2 4 9
Wyoming§ — 0 2 8 7 — 0 1 2 1 — 0 1 — —
Pacific 6 0 14 138 2 1 0 7 19 18 4 40 59 659 848
Alaska — 0 9 57 — — 0 5 15 11 — 0 0 — —
California 6 0 12 81 — 1 0 2 4 — — 35 54 573 752
Hawaii — 0 1 — 2 — 0 1 — 7 — 0 3 11 16
Oregon — 0 0 — — — 0 0 — — — 0 5 6 20
Washington — 0 0 — — — 0 0 — — 4 3 7 69 60
American Samoa — 0 0 — — — 0 0 — — — 0 0 — —
C.N.M.I. — — — — — — — — — — — — — — —
Guam — 0 0 — — — 0 0 — — — 0 0 — —
Puerto Rico — 0 0 — — — 0 0 — — — 4 17 73 77
U.S. Virgin Islands — 0 0 — — — 0 0 — — — 0 0 — —
C.N.M.I.: Commonwealth of Northern Mariana Islands.
U: Unavailable.   —: No reported cases.   N: Not reportable.   NN: Not Nationally Notifiable.   Cum: Cumulative year-to-date counts.   Med: Median.   Max: Maximum.
* Incidence data for reporting years 2009 and 2010 are provisional.
† Includes drug resistant and susceptible cases of invasive Streptococcus pneumoniae disease among children <5 years and among all ages. Case definition: Isolation of S. pneumoniae from 
a normally sterile body site (e.g., blood or cerebrospinal fluid).
§ Contains data reported through the National Electronic Disease Surveillance System (NEDSS).
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TABLE II. (Continued) Provisional cases of selected notifiable diseases, United States, weeks ending May 22, 2010, and May 23, 2009 (20th week)*
West Nile virus disease†
Reporting area
Varicella (chickenpox)§ Neuroinvasive Nonneuroinvasive¶
Current 
week












Previous 52 weeks Cum 
2010
Cum 
2009Med Max Med Max Med Max
United States 265 329 772 6,481 11,657 — 0 46 1 3 — 0 49 — 4
New England 4 17 38 288 456 — 0 0 — — — 0 0 — —
Connecticut 4 7 23 119 227 — 0 0 — — — 0 0 — —
Maine§ — 4 15 96 74 — 0 0 — — — 0 0 — —
Massachusetts — 0 0 — 2 — 0 0 — — — 0 0 — —
New Hampshire — 3 10 53 95 — 0 0 — — — 0 0 — —
Rhode Island§ — 1 12 8 16 — 0 0 — — — 0 0 — —
Vermont§ — 1 10 12 42 — 0 0 — — — 0 0 — —
Mid. Atlantic 18 32 72 648 1,057 — 0 2 — — — 0 1 — —
New Jersey — 8 28 209 204 — 0 1 — — — 0 0 — —
New York (Upstate) N 0 0 N N — 0 1 — — — 0 1 — —
New York City — 0 0 — — — 0 1 — — — 0 0 — —
Pennsylvania 18 22 53 439 853 — 0 0 — — — 0 0 — —
E.N. Central 83 106 193 2,378 3,675 — 0 4 — — — 0 3 — —
Illinois 5 26 49 628 927 — 0 3 — — — 0 0 — —
Indiana§ 19 5 35 236 263 — 0 1 — — — 0 1 — —
Michigan 15 35 84 770 1,023 — 0 1 — — — 0 0 — —
Ohio 44 28 58 675 1,188 — 0 0 — — — 0 2 — —
Wisconsin — 6 57 69 274 — 0 1 — — — 0 0 — —
W.N. Central 7 13 40 251 814 — 0 5 — — — 0 11 — 1
Iowa N 0 0 N N — 0 0 — — — 0 1 — —
Kansas§ — 5 18 90 361 — 0 1 — — — 0 2 — —
Minnesota — 0 0 — — — 0 1 — — — 0 1 — —
Missouri 7 6 24 136 384 — 0 2 — — — 0 1 — —
Nebraska§ N 0 0 N N — 0 2 — — — 0 6 — —
North Dakota — 0 26 23 38 — 0 0 — — — 0 1 — —
South Dakota — 0 7 2 31 — 0 3 — — — 0 2 — 1
S. Atlantic 86 36 123 983 1,459 — 0 4 — — — 0 2 — —
Delaware§ — 0 3 10 2 — 0 0 — — — 0 0 — —
District of Columbia — 0 4 7 20 — 0 1 — — — 0 0 — —
Florida§ 57 15 54 533 753 — 0 1 — — — 0 1 — —
Georgia N 0 0 N N — 0 1 — — — 0 0 — —
Maryland§ N 0 0 N N — 0 0 — — — 0 1 — —
North Carolina N 0 0 N N — 0 0 — — — 0 0 — —
South Carolina§ 2 0 34 68 88 — 0 2 — — — 0 0 — —
Virginia§ 12 10 65 162 383 — 0 2 — — — 0 0 — —
West Virginia 15 8 26 203 213 — 0 0 — — — 0 0 — —
E.S. Central 2 6 30 125 312 — 0 6 1 — — 0 4 — —
Alabama§ 2 6 27 124 306 — 0 0 — — — 0 0 — —
Kentucky N 0 0 N N — 0 1 — — — 0 0 — —
Mississippi — 0 3 1 6 — 0 5 1 — — 0 4 — —
Tennessee§ N 0 0 N N — 0 2 — — — 0 1 — —
W.S. Central 47 73 285 1,255 2,675 — 0 19 — 2 — 0 6 — —
Arkansas§ — 5 50 69 289 — 0 1 — 1 — 0 0 — —
Louisiana 1 2 8 25 56 — 0 2 — — — 0 4 — —
Oklahoma N 0 0 N N — 0 2 — — — 0 2 — —
Texas§ 46 62 272 1,161 2,330 — 0 16 — 1 — 0 4 — —
Mountain 18 25 49 539 1,143 — 0 12 — — — 0 17 — 3
Arizona — 0 0 — — — 0 4 — — — 0 2 — —
Colorado§ 9 11 41 211 619 — 0 7 — — — 0 14 — 1
Idaho§ N 0 0 N N — 0 3 — — — 0 5 — —
Montana§ 7 2 17 98 91 — 0 1 — — — 0 1 — —
Nevada§ N 0 0 N N — 0 2 — — — 0 1 — —
New Mexico§ 1 1 7 48 81 — 0 2 — — — 0 1 — —
Utah 1 7 22 173 352 — 0 1 — — — 0 0 — 1
Wyoming§ — 0 3 9 — — 0 1 — — — 0 2 — 1
Pacific — 1 5 14 66 — 0 12 — 1 — 0 12 — —
Alaska — 0 4 14 37 — 0 0 — — — 0 0 — —
California — 0 0 — — — 0 8 — 1 — 0 6 — —
Hawaii — 0 2 — 29 — 0 0 — — — 0 0 — —
Oregon N 0 0 N N — 0 1 — — — 0 4 — —
Washington N 0 0 N N — 0 6 — — — 0 3 — —
American Samoa N 0 0 N N — 0 0 — — — 0 0 — —
C.N.M.I. — — — — — — — — — — — — — — —
Guam — 0 2 8 — — 0 0 — — — 0 0 — —
Puerto Rico — 6 30 101 244 — 0 0 — — — 0 0 — —
U.S. Virgin Islands — 0 0 — — — 0 0 — — — 0 0 — —
C.N.M.I.: Commonwealth of Northern Mariana Islands.
U: Unavailable.   —: No reported cases.   N: Not reportable.   NN: Not Nationally Notifiable.   Cum: Cumulative year-to-date counts.   Med: Median.   Max: Maximum.
* Incidence data for reporting years 2009 and 2010 are provisional. Data for HIV/AIDS, AIDS, and TB, when available, are displayed in Table IV, which appears quarterly.
† Updated weekly from reports to the Division of Vector-Borne Infectious Diseases, National Center for Zoonotic, Vector-Borne, and Enteric Diseases (ArboNET Surveillance). Data for California 
serogroup, eastern equine, Powassan, St. Louis, and western equine diseases are available in Table I.
§ Contains data reported through the National Electronic Disease Surveillance System (NEDSS).
¶ Not reportable in all states. Data from states where the condition is not reportable are excluded from this table, except starting in 2007 for the domestic arboviral diseases and influenza-
associated pediatric mortality, and in 2003 for SARS-CoV. Reporting exceptions are available at http://www.cdc.gov/ncphi/disss/nndss/phs/infdis.htm.
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TABLE III. Deaths in 122 U.S. cities,* week ending May 22, 2010 (20th week)
Reporting area
All causes, by age (years)
P&I† 
Total Reporting area




Ages ≥65 45–64 25–44 1–24 <1
All  
Ages ≥65 45–64 25–44 1–24 <1
New England 508 357 114 18 9 10 44 S. Atlantic 1,267 780 336 74 33 27 76
Boston, MA 124 74 40 3 5 2 8 Atlanta, GA 129 82 36 6 4 1 6
Bridgeport, CT 30 16 9 5 — — 1 Baltimore, MD 166 99 51 8 5 3 14
Cambridge, MA 12 11 1 — — — 2 Charlotte, NC 122 71 40 6 2 3 6
Fall River, MA 17 15 2 — — — 1 Jacksonville, FL 155 106 34 9 3 3 11
Hartford, CT 47 34 10 2 1 — 7 Miami, FL 190 111 46 14 9 6 6
Lowell, MA 19 14 3 — — 2 2 Norfolk, VA 49 13 17 4 1 1 1
Lynn, MA 6 6 — — — — 2 Richmond, VA 65 38 17 6 3 1 4
New Bedford, MA 19 14 4 1 — — 1 Savannah, GA 54 36 14 4 — — 6
New Haven, CT 28 14 11 3 — — 2 St. Petersburg, FL 48 34 10 — 1 3 2
Providence, RI 65 52 10 — 1 2 6 Tampa, FL 202 141 42 13 3 3 13
Somerville, MA 1 — 1 — — — — Washington, D.C. 78 43 26 4 2 3 7
Springfield, MA 51 40 8 1 — 2 5 Wilmington, DE 9 6 3 — — — —
Waterbury, CT 24 19 4 — — 1 2 E.S. Central 875 560 216 59 27 13 73
Worcester, MA 65 48 11 3 2 1 5 Birmingham, AL 166 113 38 11 2 2 21
Mid. Atlantic 1,749 1,225 392 65 27 39 91 Chattanooga, TN 105 68 26 3 6 2 6
Albany, NY 46 37 6 — 1 2 1 Knoxville, TN 95 73 16 3 2 1 9
Allentown, PA 29 24 5 — — — 1 Lexington, KY 68 35 24 6 2 1 3
Buffalo, NY 82 56 16 2 1 7 9 Memphis, TN 139 87 36 9 5 2 12
Camden, NJ 28 15 8 — 1 4 — Mobile, AL 89 57 20 11 — 1 6
Elizabeth, NJ 10 9 1 — — — — Montgomery, AL 51 27 16 5 3 — 3
Erie, PA 35 30 3 2 — — 4 Nashville, TN 162 100 40 11 7 4 13
Jersey City, NJ 27 13 13 1 — — 2 W.S. Central 1,119 733 263 65 21 37 64
New York City, NY 1,019 710 227 47 16 18 49 Austin, TX 85 60 20 4 — 1 4
Newark, NJ 29 14 8 4 2 1 — Baton Rouge, LA 55 33 16 2 1 3 —
Paterson, NJ 20 9 10 1 — — 1 Corpus Christi, TX 65 47 11 5 1 1 4
Philadelphia, PA 134 84 38 3 5 4 4 Dallas, TX 189 114 47 19 3 6 13
Pittsburgh, PA§ 30 21 9 — — — 2 El Paso, TX 60 42 13 3 1 1 3
Reading, PA 29 21 8 — — — 1 Fort Worth, TX U U U U U U U
Rochester, NY 69 52 14 3 — — 4 Houston, TX 145 88 38 7 3 9 10
Schenectady, NY 22 15 6 1 — — 1 Little Rock, AR 91 57 25 6 2 1 4
Scranton, PA 25 21 4 — — — — New Orleans, LA U U U U U U U
Syracuse, NY 69 57 9 1 — 2 9 San Antonio, TX 255 165 59 13 8 10 15
Trenton, NJ 19 14 5 — — — 1 Shreveport, LA 66 42 15 3 2 4 6
Utica, NY 10 9 — — — 1 — Tulsa, OK 108 85 19 3 — 1 5
Yonkers, NY 17 14 2 — 1 — 2 Mountain 1,152 729 296 76 23 23 87
E.N. Central 1,978 1,314 476 104 41 43 119 Albuquerque, NM 124 79 26 11 5 3 13
Akron, OH 54 37 10 2 1 4 5 Boise, ID 62 45 12 2 1 2 8
Canton, OH 36 29 7 — — — 1 Colorado Springs, CO 69 39 26 3 1 — 1
Chicago, IL 305 201 69 22 9 4 5 Denver, CO 79 47 23 5 2 2 10
Cincinnati, OH 96 65 17 5 2 7 9 Las Vegas, NV 272 176 74 15 5 2 22
Cleveland, OH 249 181 46 12 5 5 12 Ogden, UT 33 21 8 2 — 2 3
Columbus, OH 144 97 37 5 2 3 10 Phoenix, AZ 202 112 58 18 7 7 13
Dayton, OH 134 88 41 4 1 — 12 Pueblo, CO 34 27 6 1 — — 2
Detroit, MI 167 78 68 14 5 2 6 Salt Lake City, UT 126 79 30 13 — 4 5
Evansville, IN 39 28 9 2 — — 4 Tucson, AZ 151 104 33 6 2 1 10
Fort Wayne, IN 68 49 15 3 — 1 5 Pacific 1,413 985 302 75 30 21 138
Gary, IN 10 4 4 — — 2 — Berkeley, CA 10 7 3 — — — 3
Grand Rapids, MI 43 30 11 1 1 — 3 Fresno, CA 128 85 30 9 2 2 15
Indianapolis, IN 207 121 65 11 4 6 11 Glendale, CA 31 23 6 2 — — 4
Lansing, MI 41 31 10 — — — 3 Honolulu, HI 72 53 15 3 1 — 10
Milwaukee, WI 87 58 20 6 2 1 7 Long Beach, CA U U U U U U U
Peoria, IL 46 30 8 3 4 1 6 Los Angeles, CA 223 153 47 9 9 5 23
Rockford, IL 45 32 7 3 1 2 1 Pasadena, CA 17 16 1 — — — 3
South Bend, IN 47 35 6 4 1 1 5 Portland, OR 117 76 28 9 3 1 8
Toledo, OH 103 75 15 7 3 3 10 Sacramento, CA 190 129 42 11 2 6 20
Youngstown, OH 57 45 11 — — 1 4 San Diego, CA 206 159 42 4 1 — 13
W.N. Central 632 439 131 35 12 15 44 San Francisco, CA 113 80 22 10 1 — 22
Des Moines, IA 148 112 29 5 2 — 13 San Jose, CA U U U U U U U
Duluth, MN 32 27 3 1 — 1 2 Santa Cruz, CA 29 19 9 1 — — 2
Kansas City, KS 27 16 8 2 1 — 1 Seattle, WA 112 76 20 9 4 3 9
Kansas City, MO 105 68 24 8 2 3 4 Spokane, WA 58 39 15 1 1 2 4
Lincoln, NE 36 27 6 1 1 1 1 Tacoma, WA 107 70 22 7 6 2 2
Minneapolis, MN 60 31 18 6 1 4 3 Total¶ 10,693 7,122 2,526 571 223 228 736
Omaha, NE 78 56 16 4 1 1 7
St. Louis, MO 4 1 — 2 1 — 1
St. Paul, MN 69 53 9 1 3 3 7
Wichita, KS 73 48 18 5 — 2 5
U: Unavailable.   —: No reported cases.   
* Mortality data in this table are voluntarily reported from 122 cities in the United States, most of which have populations of >100,000. A death is reported by the place of its occurrence and 
by the week that the death certificate was filed. Fetal deaths are not included.
† Pneumonia and influenza.
§ Because of changes in reporting methods in this Pennsylvania city, these numbers are partial counts for the current week. Complete counts will be available in 4 to 6 weeks.
¶ Total includes unknown ages.
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